CN116813786A - anti-CD 73 antibody and application thereof - Google Patents
anti-CD 73 antibody and application thereof Download PDFInfo
- Publication number
- CN116813786A CN116813786A CN202310968592.5A CN202310968592A CN116813786A CN 116813786 A CN116813786 A CN 116813786A CN 202310968592 A CN202310968592 A CN 202310968592A CN 116813786 A CN116813786 A CN 116813786A
- Authority
- CN
- China
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- sequences shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims abstract description 354
- 108091007433 antigens Proteins 0.000 claims abstract description 352
- 102000036639 antigens Human genes 0.000 claims abstract description 352
- 230000027455 binding Effects 0.000 claims abstract description 352
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims abstract description 34
- 102100022464 5'-nucleotidase Human genes 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims description 115
- 230000035772 mutation Effects 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 100
- 239000012634 fragment Substances 0.000 claims description 87
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 49
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 41
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 26
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 25
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 24
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 23
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 210000004899 c-terminal region Anatomy 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- -1 c-Met Proteins 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 229940127121 immunoconjugate Drugs 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 7
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000012202 endocytosis Effects 0.000 claims description 6
- 102000045309 human NT5E Human genes 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 3
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 3
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims description 3
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims description 3
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 101150007233 FAP2 gene Proteins 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 102000002029 Claudin Human genes 0.000 claims 1
- 108050009302 Claudin Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000002147 killing effect Effects 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 109
- 229940024606 amino acid Drugs 0.000 description 100
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000008096 B7-H1 Antigen Human genes 0.000 description 23
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 230000000903 blocking effect Effects 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 16
- 239000013641 positive control Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000283707 Capra Species 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241001416177 Vicugna pacos Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108700004024 5'-Nucleotidase Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000048776 human CD274 Human genes 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 102000004008 5'-Nucleotidase Human genes 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 108010081667 aflibercept Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 108010026668 snake venom protein C activator Proteins 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100012887 Drosophila melanogaster btl gene Proteins 0.000 description 1
- 101100012878 Drosophila melanogaster htl gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008235 cell cycle pathway Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
Abstract
The invention provides anti-CD 73 antibodies and uses thereof. The antibodies provided are capable of specifically binding CD73. The provided antibody has high affinity and specificity with antigen, has the effect of killing tumor, and can be applied to treating tumor.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to an anti-CD 73 antibody and application thereof.
Background
CD73, also known as extracellular-5 '-nucleotidase (ecto-5' NT, EC 3.1.3.5), has a protein molecular weight of about 70kDa and is an enzyme with Glucosyl Phosphatidylinositol (GPI) anchored on the cell surface. CD73 is present in most tissues, especially in the endothelial and hematopoietic cell subsets (Resta et al, immunol Rev 1998;161:95-109 and Colgan et al, prinergic Signal 2006; 2:351-60). CD39 upstream of CD73 can catalyze ATP to produce Adenosine Monophosphate (AMP), which is catalytically hydrolyzed by CD73 to adenosine. Adenosine is a widely studied signaling molecule whose biological effects are mediated by several receptors, including A1, A2A, A B and A3. In the tumor microenvironment, adenosine may not only enhance proliferation, angiogenesis and metastasis of tumors (Zhang et al, cancer Res 2010; 70:6407-11), but also significantly inhibit anti-tumor immune responses (f.ghirinhelleli et al, biomed. Res, int.2012). CD73 is therefore considered a powerful cancer therapeutic target.
CD73 is expressed on many different cancers, including colorectal Cancer, lung Cancer, pancreatic Cancer, ovarian Cancer, bladder Cancer, leukemia, glioma, glioblastoma, melanoma, thyroid Cancer, esophageal Cancer, prostate Cancer, and breast Cancer (Jin et al, cancer Res 2010;70:2245-55 and Stagg et al, PNAS2010; 107:1547-52). CD73 also affects various aspects of tumorigenesis, such as proliferation, differentiation, adhesion/migration, angiogenesis, and metastasis. It promotes proliferation of tumor cells by modulating cell cycle, apoptosis and signaling pathways such as EGFR, beta-catenin/cyclin D1, VEGF and AKT/ERK (Zhi X et al, clin Exp Metastasis 2007,24 (6): 439-448;Turcotte M etal, cancer Res2015,75 (21): 4494-4503; wu R et al, oncol Rep2016,35 (3): 1750-1756; gao ZW et al, BMC Cancer2017,17 (1): 135). Moreover, the high expression of CD73 is used as a biomarker and is closely related to the poor prognosis of various types of tumors, including breast cancer, lung cancer, ovarian cancer, gastric cancer, renal cancer, head and neck cancer and the like. In addition to cancer cells, various immune cells such as B cells, T cells, th cells, cd8+ T cells, and the like also express CD73 molecules (Ghasem G et al, 2019,23:2, 127-142). Given the critical role of CD73 in tumor growth and metastasis, it has become one of the hot targets in the field of tumor immunotherapy, and many companies have been in clinical phase 2 or clinical phase 1 studies, and no drugs have been marketed for this target.
Disclosure of Invention
The present invention provides anti-CD 73 antibodies and their use in the treatment of disease. The provided antibodies are capable of specifically binding CD73, exhibiting anti-tumor effects.
In a first aspect the invention provides an anti-CD 73 antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region: comprises the HCDR sequences shown in SEQ ID NO. 1, 2 and 3, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 1, 2 and 3; or comprises the HCDR sequences shown in SEQ ID NOs 4, 5 and 6, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOs 4, 5 and 6; or comprises the HCDR sequences shown in SEQ ID NO. 7, 8 and 9, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 7, 8 and 9; or comprises the HCDR sequences shown in SEQ ID NOS 10, 11 and 12, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS 10, 11 and 12; or comprises the HCDR sequences shown in SEQ ID NO 13, 14 and 15, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO 13, 14 and 15; or comprises the HCDR sequences shown in SEQ ID NOS.16, 17 and 18, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS.16, 17 and 18; or comprises the HCDR sequences shown in SEQ ID NO. 19, 20 and 21, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 19, 20 and 21; the light chain variable region: comprises the LCDR sequences shown in SEQ ID NOs 22, 23 and 24, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs 22, 23 and 24; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 25, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 25; or comprises the LCDR sequences shown in SEQ ID NOS.26, 27 and 28, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.26, 27 and 28; or comprises the LCDR sequences shown in SEQ ID NOS.29, 30 and 31, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.29, 30 and 31; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 32, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 32; or comprises the LCDR sequences shown in SEQ ID NOS.33, 34 and 35, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.33, 34 and 35; or comprises the LCDR sequences shown in SEQ ID NOS.36, 37 and 38, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.36, 37 and 38.
In a second aspect the invention provides an antibody or antigen binding fragment against CD73 comprising a heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising complementarity determining regions LCDR1, LCDR2 and LCDR3 wherein HCDR1 is selected from the sequences shown as SEQ ID No. 1 or 4 or 7 or 10 or 13 or 16 or 19, HCDR2 is selected from the sequences shown as SEQ ID No. 2 or 5 or 8 or 11 or 14 or 17 or 20, HCDR3 is selected from the sequences shown as SEQ ID No. 3 or 6 or 9 or 12 or 15 or 18 or 21, LCDR1 is selected from the sequences shown as SEQ ID No. 22 or 26 or 29 or 33 or 36, LCDR2 is selected from the sequences shown as SEQ ID No. 23 or 27 or 30 or 34 or 37, LCDR3 is selected from the sequences shown as SEQ ID No. 24 or 25 or 28 or 31 or 32 or 35 or 38.
In a third aspect the invention provides an anti-CD 73 antibody or antigen-binding fragment comprising: the HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO 39 or 40 or 41 or 42 or 43 or 44 or 45 and the LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO 46 or 47 or 48 or 49 or 50 or 51 or 52.
In a fourth aspect the invention provides a bispecific antibody comprising a first antigen binding portion and a second antigen binding portion; a first antigen binding portion that specifically binds a first epitope, the first antigen binding portion comprising a heavy chain variable region comprising the HCDR sequences of SEQ ID NOs 1, 2 and 3 or a sequence having one, two or three conservative amino acid mutations with the HCDR sequences of SEQ ID NOs 1, 2 and 3; or comprises the HCDR sequences shown in SEQ ID NOs 4, 5 and 6, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOs 4, 5 and 6; or comprises the HCDR sequences shown in SEQ ID NO. 7, 8 and 9, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 7, 8 and 9; or comprises the HCDR sequences shown in SEQ ID NOS 10, 11 and 12, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS 10, 11 and 12; or comprises the HCDR sequences shown in SEQ ID NO 13, 14 and 15, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO 13, 14 and 15; or comprises the HCDR sequences shown in SEQ ID NOS.16, 17 and 18, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS.16, 17 and 18; or comprises the HCDR sequences shown in SEQ ID NO. 19, 20 and 21, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 19, 20 and 21; the light chain variable region comprises the LCDR sequences shown in SEQ ID NOs 22, 23 and 24, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs 22, 23 and 24; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 25, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 25; or comprises the LCDR sequences shown in SEQ ID NOS.26, 27 and 28, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.26, 27 and 28; or comprises the LCDR sequences shown in SEQ ID NOS.29, 30 and 31, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.29, 30 and 31; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 32, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 32; or comprises the LCDR sequences shown in SEQ ID NOS.33, 34 and 35, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.33, 34 and 35; or comprises the LCDR sequences shown in SEQ ID NOS.36, 37 and 38, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.36, 37 and 38;
The second antigen binding portion specifically binds to a second epitope, and the second antigen binding portion is fused to the first antigen binding portion.
In a fifth aspect of the invention there is provided a bispecific antibody comprising a first antigen binding portion and a second antigen binding portion; the first antigen binding portion specifically binds a first epitope, the first antigen binding portion comprising a heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising complementarity determining regions LCDR1, LCDR2 and LCDR3; wherein HCDR1 is selected from the sequences shown in SEQ ID NO 1 or 4 or 7 or 10 or 13 or 16 or 19, HCDR2 is selected from the sequences shown in SEQ ID NO 2 or 5 or 8 or 11 or 14 or 17 or 20, HCDR3 is selected from the sequences shown in SEQ ID NO 3 or 6 or 9 or 12 or 15 or 18 or 21, LCDR1 is selected from the sequences shown in SEQ ID NO 22 or 26 or 29 or 33 or 36, LCDR2 is selected from the sequences shown in SEQ ID NO 23 or 27 or 30 or 34 or 37, LCDR3 is selected from the sequences shown in SEQ ID NO 24 or 25 or 28 or 31 or 32 or 35 or 38; the second antigen binding portion specifically binds to a second epitope, and the second antigen binding portion is fused to the first antigen binding portion.
In a sixth aspect the invention provides a polynucleotide encoding an antibody or antigen-binding fragment according to any one of the first to third aspects above, or encoding a bispecific antibody according to any one of the fourth to fifth aspects.
In a seventh aspect the invention provides a construct comprising a polynucleotide according to the sixth aspect above.
In an eighth aspect, the invention provides a host cell comprising a polynucleotide as described in the sixth aspect or a construct as described in the seventh aspect.
A ninth aspect of the present invention provides a pharmaceutical composition comprising: the antibody or antigen-binding fragment of any one of the first to third aspects above, or the bispecific antibody of the fourth to fifth aspects above; and a pharmaceutically acceptable carrier.
According to a tenth aspect of the present invention there is provided an antibody conjugate comprising an antibody or antigen-binding fragment as described in any one of the first to third aspects above, or a bispecific antibody as described in the fourth to fifth aspects; and a functional small molecule linked to the antibody or antigen-binding fragment or to the bispecific antibody.
An eleventh aspect of the present invention provides a kit comprising an antibody or antigen-binding fragment according to any one of the first to third aspects, or a bispecific antibody according to any one of the fourth to fifth aspects described above.
In a twelfth aspect the present invention provides a method of producing an antibody or antigen binding fragment as described above or producing a bispecific antibody as described above, comprising: culturing the host cell of the eighth aspect, and collecting the antibody or antigen-binding fragment or the bispecific antibody from the culture.
A thirteenth aspect of the invention provides a method of preventing and/or treating a disease comprising: administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment of any one of the first to third aspects, or a bispecific antibody of any one of the fourth to fifth aspects, or a pharmaceutical composition of the ninth aspect, or an antibody conjugate of the tenth aspect.
A fourteenth aspect of the present invention provides the use of an antibody or antigen-binding fragment according to any one of the first to third aspects, or a bispecific antibody according to any one of the fourth to fifth aspects, for the preparation of a medicament or kit or for the preparation of an antibody conjugate.
Drawings
Fig. 1 is a schematic structural diagram of a bispecific antibody provided according to an embodiment of the present invention.
Fig. 2 is a schematic structural diagram of a bispecific antibody provided according to an embodiment of the present invention.
Fig. 3 is a schematic structural diagram of a bispecific antibody provided according to an embodiment of the present invention.
Fig. 4 is a schematic structural diagram of a bispecific antibody provided according to an embodiment of the present invention.
Fig. 5 is a schematic structural diagram of a bispecific antibody provided according to an embodiment of the present invention.
FIG. 6 is a graph of endocytosis results of different anti-CD 73 antibodies provided according to an embodiment of the present invention.
FIG. 7 is a graph showing the anti-tumor effect of different anti-CD 73 antibodies combined with anti-PD-L1 antibodies according to an embodiment of the present invention.
FIG. 8 is a graph showing the results of blocking the enzymatic activity of different bispecific antibodies provided in accordance with an embodiment of the present invention.
Detailed Description
The following describes the technical scheme of the present invention in detail with reference to specific examples. Meanwhile, in order to facilitate understanding by those skilled in the art, it is to be noted that some terms of the present invention are explained and illustrated only for convenience of understanding by those skilled in the art, and should not be construed as limiting the scope of the present invention.
As used in this specification and the claims, "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
The term "antibody" is used herein in its broadest sense to refer to a protein or polypeptide comprising an antigen binding site or antigen binding fragment or antigen binding portion, and encompasses natural and artificial antibodies of various structures, including but not limited to whole antibody forms or antigen binding fragments of antibodies. According to a specific embodiment, the mentioned antibodies are monoclonal antibodies.
Herein, the term "bispecific antibody" comprises both an antigen binding moiety that specifically binds to different epitopes of at least two different biomolecules, and an antigen binding moiety that specifically binds to at least two epitopes of the same biomolecule. For the sake of distinction, the portions of bispecific antibodies that bind to different epitopes of the same antigen or different antigens are described as "first antigen binding portion" and "second antigen binding portion", respectively, etc. The first antigen binding portion and the second antigen binding portion are not indicative of importance, nor of the order of binding to the antigen, only for distinguishing between different epitopes of the antigen or for distinguishing between binding to different antigens. The "first antigen binding portion" and "second antigen binding portion" will also be explained and described below. The order of binding to the antigen in the listed bispecific antibodies is arbitrary unless otherwise indicated. Of course, bispecific antibodies, when specifically binding to different biomolecules, are likely to bind to more than one epitope of that particular biomolecule. According to a preferred embodiment of the invention, the bispecific antibody comprises an antigen binding moiety that specifically binds to different epitopes of two different target antigens.
Herein, "whole antibody" or "whole antibody" and the like are used to represent the same meaning, indicating a protein comprising at least two heavy chains (H) and two light chains (L) disulfide-linked to each other. Each heavy chain consists of a heavy chain variable region (abbreviated VH) and a heavy chain constant region (abbreviated CH). The heavy chain constant region includes a heavy chain constant domain CH1, a heavy chain constant domain CH2, and a heavy chain constant domain CH3. Each light chain consists of a light chain variable region (abbreviated VL) and a light chain constant domain CL. The VH and VL regions may be further divided into complementarity determining regions (also known as hypervariable or hypervariable regions, abbreviated CDRs) separated by conserved Framework Regions (FR). Each VH and VL comprises three CDRs and four FRs, arranged from amino-terminus (N-terminus) to carboxy-terminus (C-terminus) according to the following sequence: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. CDRs of the heavy chain variable region are referred to as HCDR1, HCDR2 and HCDR3, respectively, from the amino terminus, and CDRs of the light chain variable region are referred to as LCDR1, LCDR2 and LCDR3, respectively, from the amino terminus.
An "antigen binding fragment" or "antigen binding portion" (e.g., first antigen binding portion, second antigen binding portion) or "antigen binding site" is meant to encompass a portion of a full-length antibody that exhibits antigen binding properties or functions. The term "variable region" or "variable domain" refers to a domain that involves binding of an antigen to an antibody heavy or light chain. As mentioned above, hypervariable or hypervariable regions of the heavy and light chains of an intact antibody exhibit specific binding to an antigen. Examples of antigen binding fragments or antigen binding portions include, but are not limited to, fab ', F (ab ') 2, bispecific Fab ' and Fv fragments (variable regions), linear antibodies, single chain antibodies, single domain antibodies, and the like. The complete antibody is digested with papain to produce two identical antigen binding fragments, called Fab fragments, each of which contains heavy and light chain variable regions and light and heavy chain constant domains CH1.Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain constant domain CH1, including one or more cysteines from the antibody hinge region. The complete antibody was digested with pepsin to obtain F (ab') 2 fragments. The F (ab ') 2 fragment has two antigen binding F (ab) moieties linked together by disulfide bonds, and the F (ab') 2 fragment is a diabody. Single chain antibodies are fusion proteins formed by joining the heavy and light chain variable regions of an antibody via a flexible short peptide of about 10-25 amino acids. Single domain antibodies are antibody fragments consisting of variable domains of a single monomer. Single domain antibodies are also commonly referred to as nanobodies, since they are typically derived from the variable region of the heavy chain of camelid antibodies or shark antibodies. Nanobodies contain only heavy chain CDR regions and are the smallest antigen-binding fragments with complete function. Nanobodies include three CDR regions (CDR 1-CDR 3) and four framework regions FR (FR 1-FR 4). The framework regions FR1, FR2, FR3 and FR4 are separated by complementarity determining regions CDR1, CDR2 and CDR3, respectively. Antigen binding fragments may be obtained recombinantly. For example, a nucleic acid encoding the antigen-binding portion of interest may be constructed, introduced into an expression vector, and expressed in a suitable host to produce the antigen-binding fragment.
The term "and/or" when used in connection with two or more selectable items is understood to mean any one of the selectable items or any two or more of the selectable items.
The term "comprising" or "comprises" is intended to include the stated elements or steps but does not exclude other elements or steps. Of course, unless otherwise indicated, inclusion or inclusion also encompasses a situation consisting of the recited elements or steps. For example, when referring to an antibody variable region comprising a particular sequence, it is also intended to encompass antibody variable regions consisting of that particular sequence.
Reference herein to "affinity" or "binding affinity" is understood in accordance with the ordinary meaning in the art to reflect the strength and/or stability between an antigen and a binding site on an antibody or antigen binding fragment.
"specific binding" or "specifically binding to", "binding", "specifically targeting" a particular antigen or epitope, or "specific for" a particular antigen or epitope, or "capable of binding" means being distinguished from non-specific interactions, such specific binding can be measured by some method commonly used in the art. The ability of an antibody to bind to an antigen may be measured by an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art. For example, the competitive binding of the antibody to be detected and the labeled antibody can be detected by detecting the cells carrying the antigen by flow cytometry and measuring the positive rate index of the cells. The antigen space structure on the cell surface is closer to the form existing in the body, so that the method can reflect the real situation more. In connection with particular embodiments of the present invention, anti-CD 73 antibodies are provided having EC50 values of 10nM or less, 5nM or less, 1nM or less, 0.5nM or less, 0.1nM or less, 0.09nM or less, 0.08nM or less, 0.07nM or less, 0.06nM or less, 0.05nM or less, 0.04nM or less, 0.03nM or less, 0.02nM or less, and 0.01nM or less. In combination with embodiments of the invention, bispecific antibodies are provided having EC50 values of 10nM or less, 5nM or less, 1nM or less, 0.5nM or less, 0.1nM or less, 0.09nM or less, 0.08nM or less, 0.07nM or less, 0.06nM or less, 0.05nM or less, 0.04nM or less, 0.03nM or less, 0.02nM or less, 0.01nM or less, and EC50 values of 10nM or less, 5nM or less, 1nM or less, 0.5nM or less, 0.1nM or less, 0.09nM or less, 0.08nM or less, 0.07nM or less, 0.06nM or less, 0.05nM or less, 0.04nM or less, 0.03nM or less, 0.02nM or less, 0.01nM or less with PD-L1 antigen. In addition, the binding activity of antibodies to antigens can be determined by Surface Plasmon Resonance (SPR) or biological thin film interference (BLI).
Provided herein are antibodies or antigen binding fragments, bispecific antibodies, or polynucleotides, generally, that are isolatable or recombinant. "isolatable" means capable of being identified and isolated and/or recovered from a cell or cell culture expressing a polypeptide or protein. Typically, the isolated polypeptide will be prepared by at least one purification step. By "isolated antibody" is meant that it is substantially free of other antibodies or antigen-binding fragments thereof having different antigen specificities. "recombinant" means that antibodies can be produced in a foreign host cell using genetic recombination techniques.
"humanized" antibodies generally refer to antibodies based on antigen binding portions derived from non-human species, and based on the partial structure and sequence composition of human immunoglobulin molecules. For example, in humanized antibodies, the entire antibody, except the CDRs, is encoded by polynucleotides of human origin that retain antigen binding activity while reducing immunogenicity.
The CDR sequences of the antibodies or bispecific antibodies shown herein can be obtained in conjunction with existing database analysis. The CDR sequences of the first antigen binding portion and the CDR sequences of the second antigen binding portion of the provided anti-CD 73 antibodies or bispecific antibodies are obtained in combination with IMGT definition schemes (Ehrenmann f., kaas q.and Lefranc m. -p.nucleic Acids res.,38:d301-D307 (2010); ehrenmann, f., lefranc, m. -p.cold Spring Harbor protoc.,6:737-749 (2011)). It is also obtainable by the definition scheme Kabat (see, for example, U.S. Dept. Of Health and Human Servies, "Sequences of Proteins of Immunological Interest" (1983)), chothia (see, for example, J.Mol. Biol.196:901-917 (1987)), and the like. It will be appreciated by those skilled in the art that differences in the CDRs due to differences in the definition of the methods are also within the scope of the present invention.
Antibodies or antigen binding fragments
The present invention provides an anti-CD 73 antibody or antigen binding fragment comprising the HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO 39 or 40 or 41 or 42 or 43 or 44 or 45, and the LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO 46 or 47 or 48 or 49 or 50 or 51 or 52. Antibodies or antigen binding fragments are provided which contain the HCDR1, HCDR2 and HCDR3 sequences, as well as the LCDR1, LCDR2 and LCDR3 sequences, which are obtainable via the variable heavy chain regions of SEQ ID NO 39 or 40 or 41 or 42 or 43 or 44 or 45 in combination with the variable light chain regions of SEQ ID NO 46 or 47 or 48 or 49 or 50 or 51 or 52 in combination with the variable heavy chain regions of the different definition schemes. CDR sequences obtained via these heavy chain variable region and light chain variable region may also form different heavy chain variable region or light chain variable region sequences with framework region sequences of different origins as part of an anti-CD 73 antibody, for example, when forming heavy chain variable region or light chain variable region sequences. Such variations are intended to be included within the scope of the present invention.
According to an embodiment of the present invention there is provided an anti-CD 73 antibody or antigen binding fragment comprising a heavy chain variable region comprising the HCDR sequences of SEQ ID NOs 1, 2 and 3 or a sequence having one, two or three conservative amino acid mutations with the HCDR sequences of SEQ ID NOs 1, 2 and 3; or comprises the HCDR sequences shown in SEQ ID NOs 4, 5 and 6, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOs 4, 5 and 6; or comprises the HCDR sequences shown in SEQ ID NO. 7, 8 and 9, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 7, 8 and 9; or comprises the HCDR sequences shown in SEQ ID NOS 10, 11 and 12, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS 10, 11 and 12; or comprises the HCDR sequences shown in SEQ ID NO 13, 14 and 15, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO 13, 14 and 15; or comprises the HCDR sequences shown in SEQ ID NOS.16, 17 and 18, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS.16, 17 and 18; or comprises the HCDR sequences shown in SEQ ID NO. 19, 20 and 21, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 19, 20 and 21; the light chain variable region comprises the LCDR sequences shown in SEQ ID NOs 22, 23 and 24, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs 22, 23 and 24; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 25, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 25; or comprises the LCDR sequences shown in SEQ ID NOS.26, 27 and 28, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.26, 27 and 28; or comprises the LCDR sequences shown in SEQ ID NOS.29, 30 and 31, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.29, 30 and 31; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 32, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 32; or comprises the LCDR sequences shown in SEQ ID NOS.33, 34 and 35, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.33, 34 and 35; or comprises the LCDR sequences shown in SEQ ID NOS.36, 37 and 38, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.36, 37 and 38.
As used herein, a "conservative amino acid mutation" refers to an amino acid mutation that does not cause a significant change in the conformational structure of a protein or polypeptide, while retaining its biological activity. The conservative amino acid mutations mentioned may be mutations between different amino acids having similar physiological and biochemical properties. For example, through conservative amino acid mutations, the provided antibodies still retain specific binding activity for CD 73. According to embodiments, the conservative amino acid mutations mentioned may be substitutions, deletions or additions of conservative amino acids. According to specific embodiments, the deletion of a conserved amino acid is one amino acid, two amino acids or three amino acids based on the listed CDR sequences. According to specific embodiments, the conservative amino acid increase is one amino acid, two amino acids or three amino acids increase based on the CDR sequences listed. According to a specific embodiment, "conservative amino acid substitution" means the replacement of another amino acid residue with a different amino acid residue having a side chain with similar physiochemical properties. For example, conservative amino acid substitutions may occur between amino acid residues with hydrophobic side chains (e.g., met, ala, val, leu and Ile), between residues with neutral hydrophilic side chains (e.g., cys, ser, thr, asn and gin), between residues with acidic side chains (e.g., asp, glu), between amino acids with basic side chains (e.g., his, lys, and Arg), or between residues with aromatic side chains (e.g., trp, tyr, and Phe). As is known in the art, conservative amino acid substitutions typically do not cause a significant change in the conformational structure of the protein, and thus may preserve the biological activity of the protein. The conservative amino acid substitutions mentioned may be 1 conservative amino acid substitution, 2 conservative amino acid substitutions, 3 conservative amino acid substitutions, etc. The names of amino acids used herein are indicated by single-letter or three-letter codes that are standard in the art. In some embodiments, the provided HCDR sequences have one conservative amino acid substitution with the HCDR sequences shown. In some embodiments, the provided HCDR sequences have a conserved amino acid deletion from the illustrated HCDR sequences. In some embodiments, the HCDR sequences provided have one conservative amino acid increase from the HCDR sequences shown. In some embodiments, the provided LCDR sequences have one conservative amino acid substitution with the illustrated LCDR sequences. In some embodiments, the provided LCDR sequences have one conservative amino acid deletion from the illustrated LCDR sequences. In some embodiments, the provided LCDR sequences have one conservative amino acid increase from the LCDR sequences shown.
The invention also provides an anti-CD 73 antibody or antigen binding fragment comprising a heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2 and HCDR3, and a light chain variable region comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein HCDR1 is selected from the sequences shown by SEQ ID NOs 1 or 4 or 7 or 10 or 13 or 16 or 19, HCDR2 is selected from the sequences shown by SEQ ID NOs 2 or 5 or 8 or 11 or 14 or 17 or 20, HCDR3 is selected from the sequences shown by SEQ ID NOs 3 or 6 or 9 or 12 or 15 or 18 or 21, LCDR1 is selected from the sequences shown by SEQ ID NOs 22 or 26 or 29 or 33 or 36, LCDR2 is selected from the sequences shown by SEQ ID NOs 23 or 27 or 30 or 34 or 37, LCDR3 is selected from the sequences shown by SEQ ID NOs 24 or 25 or 28 or 31 or 32 or 35 or 38.
According to a specific embodiment, an antibody or antigen binding fragment thereof is provided comprising the HCDR sequences set forth in SEQ ID NOS: 1, 2 and 3, and the LCDR sequences set forth in SEQ ID NOS: 22, 23 and 24. According to a specific embodiment, an antibody or antigen binding fragment thereof is provided comprising the HCDR sequences shown in SEQ ID NOS: 4, 5 and 6, and the LCDR sequences shown in SEQ ID NOS: 22, 23 and 25. According to a specific embodiment, an antibody or antigen binding fragment thereof is provided comprising the HCDR sequences shown in SEQ ID NOS: 7, 8 and 9, and the LCDR sequences shown in SEQ ID NOS: 26, 27 and 28. According to a specific embodiment, an antibody or antigen binding fragment thereof is provided comprising the HCDR sequences shown in SEQ ID NOS 10, 11 and 12, and the LCDR sequences shown in SEQ ID NOS 29, 30 and 31. According to a specific embodiment, an antibody or antigen binding fragment thereof is provided comprising the HCDR sequences shown in SEQ ID NOS 13, 14 and 15, and the LCDR sequences shown in SEQ ID NOS 22, 23 and 32. According to a specific embodiment, an antibody or antigen binding fragment thereof is provided comprising the HCDR sequences shown in SEQ ID NOS: 16, 17 and 18, and the LCDR sequences shown in SEQ ID NOS: 33, 34 and 35. According to a specific embodiment, an antibody or antigen binding fragment thereof is provided comprising the HCDR sequences shown in SEQ ID NOS: 19, 20 and 21, and the LCDR sequences shown in SEQ ID NOS: 36, 37 and 38.
In some embodiments, provided antibodies or antigen binding fragments comprise a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence set forth in SEQ ID NO:39 or 40 or 41 or 42 or 43 or 44 or 45, and the light chain variable region is a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence set forth in SEQ ID NO:46 or 47 or 48 or 49 or 50 or 51 or 52.
As used herein, "sequence identity", "sequence homology", "sequence similarity" refers to the degree to which two polypeptides or proteins or nucleotide sequences are compared and the sequences are identical. To determine the ratio of sequence identity, this can be accomplished in a variety of ways known in the art. Such as may be obtained using published software such as BLAST, ALIGN, BLAST-2. In some embodiments, sequence identity is due to conservative amino acid mutations. According to specific embodiments, the sequence having sequence identity to the heavy chain variable region or the light chain variable region described above may be due to 1 conservative amino acid mutation, 2 conservative amino acid mutations, 3 conservative amino acid mutations, 4 conservative amino acid mutations, 5 conservative amino acid mutations, 6 conservative amino acid mutations, 7 conservative amino acid mutations, 8 conservative amino acid mutations, 9 conservative amino acid mutations, or 10 conservative amino acid mutations. According to a specific embodiment, the sequence having sequence identity to the heavy chain variable region or the light chain variable region described above differs in the framework regions.
According to a specific embodiment, the antibody provided is mab309 comprising a heavy chain variable region shown in SEQ ID NO. 39 and a light chain variable region shown in SEQ ID NO. 46. According to a specific embodiment, the antibody provided is mab307, which comprises a heavy chain variable region shown in SEQ ID NO. 40 and a light chain variable region shown in SEQ ID NO. 47. According to a specific embodiment, the antibody provided is mab144 comprising a heavy chain variable region shown in SEQ ID NO. 41 and a light chain variable region shown in SEQ ID NO. 48. According to a specific embodiment, the antibody provided is mab235 comprising a heavy chain variable region shown in SEQ ID NO. 42 and a light chain variable region shown in SEQ ID NO. 49. According to a specific embodiment, an antibody is provided that is mab451 comprising a heavy chain variable region shown in SEQ ID NO. 43 and a light chain variable region shown in SEQ ID NO. 50. According to a specific embodiment, the antibody provided is mab540 comprising a heavy chain variable region shown as SEQ ID NO. 44 and a light chain variable region shown as SEQ ID NO. 51. According to a specific embodiment, the antibody provided is mab449, which comprises a heavy chain variable region as set forth in SEQ ID NO. 45 and a light chain variable region as set forth in SEQ ID NO. 52. The antibodies shown exhibit specific binding to CD73, e.g., exhibit strong specific binding activity to mammalian CD 73. The heavy chain constant domain of these antibodies is shown as SEQ ID NO. 100 and the light chain constant domain is shown as SEQ ID NO. 101.
The provided antibodies or antigen binding fragments may also be humanized. By humanization, the immunogenicity of an antibody or antigen-binding fragment can be reduced while maintaining binding activity to the target antigen. In some embodiments, antibodies or antigen binding fragments provided include a heavy chain variable region comprising a heavy chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence set forth in SEQ ID NO 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65, and a light chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence set forth in SEQ ID NO 66 or 67 or 68 or 69 or 70 or 71 or 73 or 74 or 75 or 76 or 77 or 78 or 79. According to a specific embodiment, the antibody provided is mab309hu1 comprising a heavy chain variable region shown in SEQ ID NO. 53 and a light chain variable region shown in SEQ ID NO. 66. According to a specific embodiment, the antibody provided is mab309hu3 comprising a heavy chain variable region shown in SEQ ID NO. 54 and a light chain variable region shown in SEQ ID NO. 67. According to a specific embodiment, the antibody provided is mab144hu1 comprising a heavy chain variable region shown in SEQ ID NO. 55 and a light chain variable region shown in SEQ ID NO. 68. According to a specific embodiment, the antibody provided is mab144hu2 comprising a heavy chain variable region shown in SEQ ID NO. 56 and a light chain variable region shown in SEQ ID NO. 69. According to a specific embodiment, the antibody provided is mab451hu1 comprising a heavy chain variable region shown in SEQ ID NO. 57 and a light chain variable region shown in SEQ ID NO. 70. According to a specific embodiment, the antibody provided is mab451hu3 comprising a heavy chain variable region shown in SEQ ID NO. 58 and a light chain variable region shown in SEQ ID NO. 71. According to a specific embodiment, the antibody provided is mab451hu4 comprising the heavy chain variable region shown in SEQ ID NO. 59 and the light chain variable region shown in SEQ ID NO. 72. According to a specific embodiment, the antibody provided is mab451hu5 comprising a heavy chain variable region shown in SEQ ID NO. 60 and a light chain variable region shown in SEQ ID NO. 73. According to a specific embodiment, the antibody provided is mab451hu6 comprising the heavy chain variable region shown in SEQ ID NO. 60 and the light chain variable region shown in SEQ ID NO. 74. According to a specific embodiment, the antibody provided is mab540hu1 comprising a heavy chain variable region as set forth in SEQ ID NO. 61 and a light chain variable region as set forth in SEQ ID NO. 75. According to a specific embodiment, the antibody provided is mab540hu3 comprising a heavy chain variable region shown in SEQ ID NO. 62 and a light chain variable region shown in SEQ ID NO. 76. According to a specific embodiment, the antibody provided is mab449hu1 comprising a heavy chain variable region as set forth in SEQ ID NO. 63 and a light chain variable region as set forth in SEQ ID NO. 77. According to a specific embodiment, the antibody provided is mab449hu3 comprising a heavy chain variable region as set forth in SEQ ID NO. 64 and a light chain variable region as set forth in SEQ ID NO. 78. According to a specific embodiment, the antibody provided is mab449hu4 comprising a heavy chain variable region as set forth in SEQ ID NO. 65 and a light chain variable region as set forth in SEQ ID NO. 79. The heavy chain constant domain of these antibodies is shown as SEQ ID NO. 100 and the light chain constant domain is shown as SEQ ID NO. 101.
/>
/>
According to specific embodiments, antibodies are provided that bind human CD73 or monkey (e.g., cynomolgus) CD73 with an EC50 of 10nM or less, e.g., an affinity EC50 value with CD73 of less than 5nM, less than 4nM, less than 3nM, less than 2nM, less than 1nM, less than 0.8nM, less than 0.5nM, less than 0.3nM, or less than 0.1nM, less than 0.05nM. The provided antibodies can also promote CD73 endocytosis and exhibit anti-tumor activity.
The anti-CD 73 antibody provided may be from any of the commonly known isotypes, including but not limited to IgA, igG, igM and secretory IgA. IgG isotypes can be divided into different subclasses in different species, for example, igG1, igG2, igG3 and IgG4 in humans and IgG1, igG2a, igG2b and IgG3 in mice. According to embodiments, the provided antibodies further comprise an Fc region, which may be derived from a native Fc region or an engineered Fc region. The native Fc region may be of any origin, including but not limited to murine, primate, human, preferably human. The mentioned Fc region of human origin can be obtained in a public database.
Bispecific antibodies
Bispecific antibodies (Bispecific antibody, bsAb) are antibodies that are capable of specifically binding two antigens or epitopes simultaneously. Since Nisonoff and its co-workers proposed the concept of BsAb for the first time in 1960, bispecific antibodies developed rapidly as the technology of genetically engineered antibodies became mature. Because BsAb can target multiple antigens or epitopes, it exhibits more advantages than monoclonal antibodies, and also gradually exhibits higher efficacy than monoclonal antibody combination therapies. For example, specific immune effector cells can be redirected to adjacent tumor cells to enhance tumor killing; but also the specificity of binding can be increased by the interaction of two different cell surface antigens; meanwhile, compared with the combination of single antibodies, the development cost can be reduced, and the balance of different half-lives of the two antibodies is not needed, so that the administration time is different, and the toxicity is low. Develop the bispecific antibody related to CD73 target spot, have extensive application in fields such as tumor treatment and autoimmune disease. Bispecific antibodies are used to treat diseases and exhibit excellent disease-treating effects.
The present invention provides a bispecific antibody comprising a first antigen binding moiety and a second antigen binding moiety, each of which specifically binds a different epitope. The different epitopes mentioned may be derived from different epitopes of the same antigen or may be derived from different epitopes of different antigens. According to a specific embodiment of the present invention, bispecific antibodies are provided comprising a first antigen binding moiety that specifically binds a first epitope and a second antigen binding moiety that specifically binds a second epitope, the first antigen binding moiety and the second antigen binding moiety being fused. The first epitope and the second epitope may be derived from the same antigen or may be derived from different antigens. According to a preferred embodiment of the invention, the first antigen binding portion specifically binds a first epitope and the second antigen binding portion specifically binds a second epitope from a different antigen. As used herein, the terms "first," "second," and the like are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated or as indicating a sequential order. The terms "first antigen binding portion", "second antigen binding portion" mean being capable of binding to a different antigen or the same, respectively The portions of the antigen to which different epitopes bind may be whole antibodies or may be part of whole antibodies, e.g.heavy chain variable regions, light chain variable regions, fab ', F (ab') 2 Single chain antibodies (ScFv), or single domain antibodies (sdabs), and the like.
The present invention provides a bispecific antibody comprising a first antigen binding portion and a second antigen binding portion; the first antigen binding portion specifically binds to a first epitope and the second antigen binding portion specifically binds to a second epitope; the first antigen binding portion comprises the HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region shown as SEQ ID NO 39 or 40 or 41 or 42 or 43 or 44 or 45 and the LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region shown as SEQ ID NO 46 or 47 or 48 or 49 or 50 or 51 or 52. It is noted that each of the CDR sequences mentioned may be obtained via the illustrated heavy chain variable region and light chain variable region sequences in combination with different definition schemes. Those skilled in the art will also appreciate that the CDR sequences of the heavy and light chain variable region sequences shown will also differ somewhat due to differences in the definition of antibody sequences, e.g., the classical Kabat amino acid sequence numbering system, IMGT system, chothia system, etc., as mentioned above. The different CDR sequences analyzed are all included in the scope of the present invention. These CDR sequences may form different heavy chain variable region sequences or light chain variable region sequences with framework region sequences of different origins, and these variations and differences are included within the scope of the present invention.
According to an embodiment of the present invention, there is also provided a bispecific antibody comprising a first antigen binding portion and a second antigen binding portion; the first antigen binding portion specifically binds to a first epitope, the second antigen binding portion specifically binds to a second epitope, and the second antigen binding portion is fused to the first antigen binding portion; the first antigen binding portion comprises a heavy chain variable region comprising the HCDR sequences of SEQ ID NOs 1, 2 and 3 or a sequence having one, two or three conservative amino acid mutations with the HCDR sequences of SEQ ID NOs 1, 2 and 3; or comprises the HCDR sequences shown in SEQ ID NOs 4, 5 and 6, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOs 4, 5 and 6; or comprises the HCDR sequences shown in SEQ ID NO. 7, 8 and 9, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 7, 8 and 9; or comprises the HCDR sequences shown in SEQ ID NOS 10, 11 and 12, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS 10, 11 and 12; or comprises the HCDR sequences shown in SEQ ID NO 13, 14 and 15, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO 13, 14 and 15; or comprises the HCDR sequences shown in SEQ ID NOS.16, 17 and 18, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS.16, 17 and 18; or comprises the HCDR sequences shown in SEQ ID NO. 19, 20 and 21, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 19, 20 and 21; the light chain variable region comprises the LCDR sequences shown in SEQ ID NOs 22, 23 and 24, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs 22, 23 and 24; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 25, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 25; or comprises the LCDR sequences shown in SEQ ID NOS.26, 27 and 28, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.26, 27 and 28; or comprises the LCDR sequences shown in SEQ ID NOS.29, 30 and 31, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.29, 30 and 31; or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 32, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 32; or comprises the LCDR sequences shown in SEQ ID NOS.33, 34 and 35, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.33, 34 and 35; or comprises the LCDR sequences shown in SEQ ID NOS.36, 37 and 38, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.36, 37 and 38.
The first antigen-binding portion or the second antigen-binding portion of the bispecific antibody referred to may be selected as desired for the whole antibody or only a part of the fragments thereof, provided that it is capable of targeting a different target antigen. The first antigen binding portion or the second antigen binding portion may be only the heavy chain variable region, fab ', F (ab') 2 Single chain antibodies (ScFv), trap, or single domain antibodies (sdAb), and the like.
According to a specific embodiment, bispecific antibodies are provided comprising the HCDR sequences shown in SEQ ID NOS: 1, 2, and 3, and the LCDR sequences shown in SEQ ID NOS: 22, 23, and 24. According to a specific embodiment, bispecific antibodies are provided having an HCDR sequence comprising SEQ ID NOs 4, 5 and 6 and having an LCDR sequence as shown in SEQ ID NOs 22, 23 and 25. According to a specific embodiment, bispecific antibodies are provided having a sequence comprising the HCDR sequences shown in SEQ ID NOS.7, 8, and 9, and the LCDR sequences shown in SEQ ID NOS.26, 27, and 28. According to a specific embodiment, bispecific antibodies are provided comprising the HCDR sequences shown in SEQ ID NOS 10, 11, and 12, and the LCDR sequences shown in SEQ ID NOS 29, 30, and 31. According to a specific embodiment, bispecific antibodies are provided comprising the HCDR sequences shown in SEQ ID NOS 13, 14, and 15, and the LCDR sequences shown in SEQ ID NOS 22, 23, and 32. According to a specific embodiment, bispecific antibodies are provided comprising the HCDR sequences shown in SEQ ID NOS: 16, 17, and 18, and the LCDR sequences shown in SEQ ID NOS: 33, 34, and 35. According to a specific embodiment of the present invention, bispecific antibodies are provided comprising the HCDR sequences shown in SEQ ID NOS.19, 20, and 21, and the LCDR sequences shown in SEQ ID NOS.36, 37, and 38. The HCDR sequences and LCDR sequences shown are shown as the first antigen-binding portion of a bispecific antibody, specifically binding to a target antigen.
In some embodiments, bispecific antibodies are provided that include the following heavy chain variable regions and light chain variable regions: a heavy chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence shown in SEQ ID NO 39 or 40 or 41 or 42 or 43 or 44 or 45 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 and a light chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence shown in SEQ ID NO 46 or 47 or 48 or 50 or 51 or 52 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 78 or 79. Wherein SEQ ID NOs 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 and 65 are each a humanized heavy chain variable region sequence. 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 and 79, respectively, are humanized light chain variable region sequences. The heavy and light chain variable region sequences are shown as the first antigen binding portion of a bispecific antibody, specifically binding to a target antigen. The sequences of the heavy and light chain variable regions of the first antigen binding portion are less immunogenic after humanization and retain binding activity to the target antigen (e.g., CD 73). Humanized antibody sequences can be obtained by methods commonly used in the art (e.g., complementarity determining region grafting methods). In some embodiments, the provided humanized antibody sequences retain CDR region sequences, replacing framework region sequences with framework region sequences of human origin. The framework region sequences of human origin can be obtained from published sequences of human origin. For example, by database alignment and computer homology modeling, searching for a human FR region template with maximum homology, comprehensively considering key residues for determining whether the FR region needs to be subjected to back mutation and restoring mutation, and obtaining the high-affinity humanized antibody. These sequences are usually described in commonly used databases, such as PDB protein structure database, IMGT, genebank, and the like.
In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 39 and a light chain variable region as set forth in SEQ ID NO. 46. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 40 and a light chain variable region shown as SEQ ID NO. 47. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 41 and a light chain variable region as set forth in SEQ ID NO. 48. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 42 and a light chain variable region as set forth in SEQ ID NO. 49. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 43 and a light chain variable region as set forth in SEQ ID NO. 50. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 44 and a light chain variable region as set forth in SEQ ID NO. 51. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 45 and a light chain variable region as set forth in SEQ ID NO. 52. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 53 and a light chain variable region as set forth in SEQ ID NO. 66. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 54 and a light chain variable region shown as SEQ ID NO. 67. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 55 and a light chain variable region as set forth in SEQ ID NO. 68. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 56 and a light chain variable region as set forth in SEQ ID NO. 69. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 57 and a light chain variable region as set forth in SEQ ID NO. 70. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 58 and a light chain variable region as set forth in SEQ ID NO. 71. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 59 and a light chain variable region as set forth in SEQ ID NO. 72. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 60 and a light chain variable region as set forth in SEQ ID NO. 73. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 60 and a light chain variable region as set forth in SEQ ID NO. 74. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 61 and a light chain variable region as set forth in SEQ ID NO. 75. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 62 and a light chain variable region as set forth in SEQ ID NO. 76. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 63 and a light chain variable region as set forth in SEQ ID NO. 77. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 64 and a light chain variable region as set forth in SEQ ID NO. 78. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 65 and a light chain variable region as set forth in SEQ ID NO. 79.
According to an embodiment of the invention, the heavy chain variable region and the heavy chain constant domain of the first antigen binding portion are linked, and the light chain variable region and the light chain constant domain of the first antigen binding portion are linked, forming an IgG type structure; the second antigen binding portion is a single domain antibody. According to a specific embodiment of the invention, the second antigen binding portion is linked directly to the carboxy terminus (C-terminus) of the Fc region or via a linker. According to a specific embodiment of the invention, the second antigen binding portion is directly linked to the amino acid (N-terminal) of the heavy chain variable region or the light chain variable region of the first antigen binding portion or is linked via a linker. According to a specific embodiment of the invention, the second antigen binding portion is directly linked to the carboxy-terminus of the light chain constant domain CL of the first antigen binding portion or is linked via a linker. Of course, when the second antigen-binding portion and the first antigen-binding portion are fused, the methods may be not limited to the above-mentioned methods, and these fusion methods may be combined or may be connected by other methods.
According to a preferred embodiment of the invention, as shown in fig. 1, the heavy chain variable region and the heavy chain constant domain of the first antigen binding portion of the bispecific antibody are linked, the light chain variable region and the light chain constant domain of the first antigen binding portion are linked to form an IgG type structure, the second antigen binding portion is a single domain antibody, the second antigen binding portion is linked to the carboxy-terminus of the Fc region through a linker, and the two single domain antibodies are linked to the two ends of the carboxy-terminus of the Fc region through linkers, respectively. The two single domain antibodies comprised by the second antigen binding portion may be the same or different. Of course, one single domain antibody or more single domain antibodies may be linked to only one end of the Fc region at the carboxy terminus, as desired. As shown in fig. 2, the second antigen-binding portion may also comprise four single-domain antibodies, as desired, with two single-domain antibodies linked to each of the two ends of the Fc region at the carboxy terminus. The single domain antibodies that are linked may be the same or different. The single domain antibodies may be linked by a linker.
According to a preferred embodiment of the invention, the heavy chain variable region and the heavy chain constant domain of the first antigen binding portion of the bispecific antibody are linked, the light chain variable region and the light chain constant domain of the first antigen binding portion are linked, forming an IgG type structure, the second antigen binding portion is a single domain antibody, and the second antigen binding portion is linked to the carboxy terminus of the light chain constant domain via a linker. In at least some embodiments, the second antigen binding portion comprises four single domain antibodies, two single domain antibodies each linked to the carboxy terminus of the light chain constant domain by a linker, as shown in fig. 3. The four single domain antibodies comprised by the second antigen binding portion may be the same or different. The second antigen binding portion may also, if desired, comprise only two single domain antibodies, one single domain antibody linked directly or via a linker to the carboxy terminus of the light chain constant domain, as shown in figure 5. The second antigen-binding portion may also comprise four single domain antibodies, one single domain antibody linked to each of the two ends of the Fc region at the carboxy terminus via a linker, and one single domain antibody linked to each of the two ends of the light chain constant domain at the carboxy terminus via a linker, as shown in FIG. 4. The single domain antibodies that are linked may be the same or different. The single domain antibodies may be linked by a linker. Fig. 1 to 5 are only schematic drawings, and for example, the interchain disulfide bond between the light chain and the heavy chain is not shown in the drawings.
According to a preferred embodiment of the invention, the first antigen binding portion is in addition to the heavy chain variable region and the light chain variable region mentioned aboveFurther comprising a heavy chain constant domain CH1 and a light chain constant domain, forming (Fab') 2 The structure, the bispecific antibody further comprises an Fc region, and the second antigen-binding portion comprises a single domain antibody, the single domain antibody being linked to the carboxy terminus of the light chain constant domain and/or to the carboxy terminus of the Fc region. The number of the single domain antibodies is not particularly required, and the single domain antibodies connected with the single domain antibodies can be the same or different.
Herein, "linker" and "linker fragment" have the same meaning. The linker may be some oligopeptide or polypeptide and may be any amino acid sequence capable of providing flexibility. Useful linkers are those commonly used in the art, including but not limited to the group consisting of: GS, SG, GGS, GSG, SGG, GGG, GGGS, SGGG, GGGGS, GGGGGSGS, GGGGSGS, GGGGSGGS, GGGGSGGGGSGGGGS, GGGGSGGGGS, GGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSGGGGSGGGGSGGGSGGGS, etc.
The second antigen binding portion referred to specifically binds to an antigen different from the first epitope, including but not limited to: PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, 4-1BB, OX40L, VEGF, VEGF trap, VEGFR, EGFR, GARP, TGF-. Beta., CD47, c-Met, CD3, CD33, TIGIT, PVRIG, CD69, CD96, LEFA1, CD226, FAP2, GITR, CEACAM-1, CD48, TIM-1, VISTA, CD39, CD70, CD27, CD40, claudin18.2, ICOS, BLTA, B7-H3, BCMA, MUC1/16, and the like. For example, a commercially available or in-flight antibody molecule sequence can be combined with the first antigen-binding portion described herein to form a bispecific antibody that can exert a therapeutic effect on a disease. Taking PD-1 antibody as an example, partial or complete sequences of antibody molecules such as Nivolumab, terlipressimab Li Shan, caprilizumab (camrelizumab), tirelizumab (tisllizumab) and the like can be fused with the first antigen-binding portion mentioned herein to form a bispecific antibody. Taking the PD-L1 antibody as an example, part or all of the sequences of the antibody molecules such as the Durvalumab (Durvalumab), the Ab (atezolizumab), the Ab (avelumab) and the like can be fused with the first antigen binding portion mentioned herein to form the bispecific antibody to play a role. For another example, the second antigen binding portion may be a VEGF trap structure. Apacetirizine (aflibercept or VEGF-trap) is able to specifically target VEGFA, VEGFB and PIGF, which by specifically binding and capturing these proteins, prevents angiogenesis. The VEGF-trap molecule and the first antigen binding portion may be combined into a bispecific antibody that exhibits therapeutic effects. Bevacizumab is a recombinant humanized immunoglobulin G1 (IgG 1) monoclonal antibody, which can bind VEGFA and inhibit the binding of VEGFR2, thereby inhibiting the biological action of VEGF. The bevacizumab or a biological analogue thereof may be fused in part or in whole to the first antigen binding portion mentioned herein, and constitutes a bispecific antibody.
According to a specific embodiment, the present invention provides a bispecific antibody comprising a first antigen binding moiety that specifically binds CD73 and a second antigen binding moiety that specifically binds PD-L1. As mentioned above, the expression form of the second antigen binding portion is not limited as long as it can specifically target PD-L1. For example, may be an intact antibody, or a portion thereof, including but not limited to heavy chain variable regions, fab ', F (ab') 2 Single chain antibodies or nanobodies, and the like. The second antigen binding portion may be obtained by screening an antibody library as desired, or may be derived from a commercially available or existing (e.g., published in the literature or clinically developed) antibody sequence. In some embodiments, the second antigen binding portion is a single domain antibody. According to a preferred embodiment of the invention, the bispecific antibody further comprises an Fc region fused to a first antigen binding moiety to an IgG type structure, and a second antigen binding moiety is linked directly to the carboxy-terminus (also known as the C-terminus) of the Fc region or via a linker.
In some embodiments, a second antigen binding portion is provided comprising CDR1, CDR2, and CDR3, wherein the CDR1 is selected from the sequences set forth in SEQ ID NOs 80, 83, or 86, or a sequence having one or two conservative amino acid mutations compared to SEQ ID NOs 80, 83, and 86; CDR2 is selected from the sequences shown in SEQ ID NOS: 81, 84 or 87, or a sequence having one or two conservative amino acid mutations compared to SEQ ID NOS: 81, 84 and 87; and CDR3 is selected from the sequences shown in SEQ ID NO 82, 85, 88 or 89, or a sequence having one, two or three conservative amino acid mutations compared to SEQ ID NO 82, 85, 88 and 89. As mentioned above, it will be appreciated by those skilled in the art that the CDR regions can be characterized using different databases, and that the sequence of the characterized CDR regions can vary and such variations are intended to be within the scope of the present invention.
According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO. 80, a CDR2 sequence as shown in SEQ ID NO. 81 and a CDR3 sequence as shown in SEQ ID NO. 82. According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO. 83, a CDR2 sequence as shown in SEQ ID NO. 84 and a CDR3 sequence as shown in SEQ ID NO. 85. According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO. 86, a CDR2 sequence as shown in SEQ ID NO. 87 and a CDR3 sequence as shown in SEQ ID NO. 88. According to a specific embodiment, the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO. 80, a CDR2 sequence as shown in SEQ ID NO. 81 and a CDR3 sequence as shown in SEQ ID NO. 89. The CDR1, CDR2 and CDR3 sequences shown may form single domain antibodies with framework region FR of different origin. The framework region FR sequence is not particularly limited and may be of murine or human origin, or may be of partially murine or partially human origin.
SEQ ID NO: | Functional area | Amino acid sequence |
80 | CDR1 | GRSFSSSG |
81 | CDR2 | INSSGGDT |
82 | CDR3 | AAKEGGGPSSIPAIYDY |
83 | CDR1 | GFTFSSYA |
84 | CDR2 | INTGSEIV |
85 | CDR3 | ATGLVSAEHDGI |
86 | CDR1 | GRDFLTYG |
87 | CDR2 | INWSGSMT |
88 | CDR3 | AARRGAVTYASSNEYEH |
89 | CDR3 | AAKEGGGPSSIPAIFDY |
In some embodiments, the second antigen binding portion has a sequence as set forth in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the sequence of the second antigen binding portion is 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence set forth in SEQ ID No. 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. The sequences shown in SEQ ID NOs 95, 96, 97, 98 and 99 are humanized antibody sequences. The provided humanized sequences have low immunogenicity and high affinity for the target protein.
/>
/>
The sequence of the second antigen binding portion is described in PCT patent application No. PCT/CN2022/110423 and International publication No. WO 2023/01614A, and the patent text describes that an anti-PD-L1 nanobody library is obtained by a alpaca immunization method, and screening and identification are carried out, so that nanobodies with good affinity and specific binding and tumor killing effects are obtained. The disclosures of PCT patent application Ser. No. PCT/CN2022/110423 and International publication No. WO 2023/01614A are also incorporated herein in their entirety or in part by reference thereto, as appropriate.
The present invention also provides a bispecific antibody comprising: a first antigen binding portion capable of binding CD73 and a second antigen binding portion capable of binding PD-L1.
According to a specific embodiment, the first antigen binding portion comprises the HCDR sequences shown in SEQ ID NOS.1, 2 and 3 and the LCDR sequences shown in SEQ ID NOS.22, 23 and 24; the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO 80 or 83 or 86, a CDR2 sequence as shown in SEQ ID NO 81 or 84 or 87, and a CDR3 sequence as shown in SEQ ID NO 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequences shown in SEQ ID NOS.4, 5 and 6, and the LCDR sequences shown in SEQ ID NOS.22, 23 and 25; the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO 80 or 83 or 86, a CDR2 sequence as shown in SEQ ID NO 81 or 84 or 87, and a CDR3 sequence as shown in SEQ ID NO 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequences shown in SEQ ID NOS.7, 8 and 9, and the LCDR sequences shown in SEQ ID NOS.26, 27 and 28; the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO 80 or 83 or 86, a CDR2 sequence as shown in SEQ ID NO 81 or 84 or 87, and a CDR3 sequence as shown in SEQ ID NO 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequences shown in SEQ ID NOS 10, 11 and 12, and the LCDR sequences shown in SEQ ID NOS 29, 30 and 31; the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO 80 or 83 or 86, a CDR2 sequence as shown in SEQ ID NO 81 or 84 or 87, and a CDR3 sequence as shown in SEQ ID NO 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequences shown in SEQ ID NOS 13, 14 and 15, and the LCDR sequences shown in SEQ ID NOS 22, 23 and 32; the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO 80 or 83 or 86, a CDR2 sequence as shown in SEQ ID NO 81 or 84 or 87, and a CDR3 sequence as shown in SEQ ID NO 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequences shown in SEQ ID NOS: 16, 17 and 18, and the LCDR sequences shown in SEQ ID NOS: 33, 34 and 35; the second antigen binding portion comprises the sequence shown in SEQ ID NO 80 or 83 or 86 CDR1 sequence shown in SEQ ID No. 81 or 84 or 87, and CDR3 sequence shown in SEQ ID No. 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion comprises the HCDR sequences shown in SEQ ID NOS.19, 20 and 21, and the LCDR sequences shown in SEQ ID NOS.36, 37 and 38; the second antigen binding portion comprises a CDR1 sequence as shown in SEQ ID NO 80 or 83 or 86, a CDR2 sequence as shown in SEQ ID NO 81 or 84 or 87, and a CDR3 sequence as shown in SEQ ID NO 82 or 85 or 88 or 89. According to a specific embodiment, the first antigen binding portion and the second antigen binding portion are bound by (G 4 S) 3-5 The connectors are connected.
In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 39, and a light chain variable region as set forth in SEQ ID NO. 46; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 40, and a light chain variable region shown as SEQ ID NO. 47; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 41 and a light chain variable region shown as SEQ ID NO. 48; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 42 and a light chain variable region as set forth in SEQ ID NO. 49; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 43 and a light chain variable region shown as SEQ ID NO. 50; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 44 and a light chain variable region shown as SEQ ID NO. 51; the second antigen binding portion comprises S EQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 45 and a light chain variable region shown as SEQ ID NO. 52; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 53 and a light chain variable region shown as SEQ ID NO. 66; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 54 and a light chain variable region shown as SEQ ID NO. 67; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 55 and a light chain variable region shown as SEQ ID NO. 68; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 56 and a light chain variable region shown as SEQ ID NO. 69; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 57 and a light chain variable region shown as SEQ ID NO. 70; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 58 and a light chain variable region shown as SEQ ID NO. 71; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 59 and a light chain variable region shown as SEQ ID NO. 72; the second antigen binding portion comprises SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 60 and a light chain variable region shown as SEQ ID NO. 73; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 60 and a light chain variable region shown as SEQ ID NO. 74; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 61 and a light chain variable region shown as SEQ ID NO. 75; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 62 and a light chain variable region as set forth in SEQ ID NO. 76; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region as set forth in SEQ ID NO. 63 and a light chain variable region as set forth in SEQ ID NO. 77; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 64 and a light chain variable region shown as SEQ ID NO. 78; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. In some embodiments, the first antigen binding portion comprises a heavy chain variable region shown as SEQ ID NO. 65 and a light chain variable region shown as SEQ ID NO. 79; the second antigen binding portion comprises the sequence shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99. According to a specific embodiment, the first antigen binding portion and the second antigen binding portion are bound by (G 4 S) 3-5 The connectors are connected.
According to a specific embodiment, the heavy chain variable region and the heavy chain constant domain of the first antigen binding portion are linked, and the light chain variable region and the light chain constant domain of the first antigen binding portion are linked, forming an IgG type structure. The IgG type structure formed may employ a natural sequence of mammalian origin (e.g., may be a natural sequence of human origin) in addition to the heavy chain variable region and light chain variable region sequences mentioned. According to a specific embodiment, the second antigen binding portion is linked to the carboxy terminus (C-terminus) of the Fc region; or the second antigen binding portion is linked to the amino terminus (N-terminus) of the heavy chain variable region or the light chain variable region of the first antigen binding portion; or the second antigen binding portion is linked to the carboxy terminus (C-terminus) of the light chain constant domain CL.
The Fc region referred to may be a native Fc region sequence or may be a modified Fc region sequence, for example, the sequence of the Fc region may be mutated. ADCC (antibody-dependent cell-mediated cytotoxicity), ADCP (antibody-dependent cell-mediated phagocytosis) or CDC (complement-mediated cytotoxicity) of antibodies can be modulated by Fc region mutations, and the like. ADCC refers to the binding of Fab fragments of antibodies to epitopes of virus-infected or tumor cells, the binding of their Fc fragments to Fc receptors (FcR) on the surface of killer cells (e.g., NK cells, macrophages, etc.), mediating the direct killing of the target cells by the killer cells. ADCP is primarily mediated by monocytes, macrophages, neutrophils and dendritic cells to phagocytose target cells. CDC is the activation of the classical pathway of complement by binding antibodies to the corresponding antigens on the cell membrane surface, forming complexes that exert lytic effects on target cells. The Fc region sequence mutation may be a mutation of one, two, three, four or five amino acids. Of course, in addition to amino acid mutations in the Fc region, mutations can also occur in other regions, such as the heavy chain constant domain CH1, the hinge region, etc. The amino acid mutations mentioned are known to those skilled in the art and include, but are not limited to, L234F, L234A, L235E, G236R, G237A, D A, K A, P329A, P331S, P331A, N297A, N297G, A330S, V309L, P238S, G236R, L328R and the like. The amino acid mutations mentioned may also be L235V, R292P, K326W, E35333S, S267E, H268F, S T, F243L, R292P, Y L, V L, V305I, P396L, S239D, I332E, A L, S298A, E333A, K334A, etc. The amino acid mutations mentioned may be selected from these mutation sites, or a combination of several mutation sites. In some embodiments, bispecific antibodies provided are substituted with a330S and P331S. In some embodiments, the bispecific antibodies provided are substituted with D270A, K322A, P329A and P331A. In some embodiments, the bispecific antibodies provided are substituted with L234F, L235E, P S and N297A. In some embodiments, the bispecific antibodies provided have the S267E, H268F and S324T mutations. In some embodiments, bispecific antibodies are provided that have undergone K214R, L234F, L235E, P331S, D356E and L358M mutations. Of course, modifications to the Fc region sequence can also be used to improve the half-life of the antibody drug, and the mutation sites for available amino acids are also known to those skilled in the art. The numbering of the mutation sites herein is according to the EU index as proposed by Kabat (Kabat, E.A. et al Sequences of Proteins of Immunological Interest.5) th Edition-USDepartment of Health and human severices,NIH publication n 91-3242,pp662,680,689(1991))。
Polynucleotide
The invention also provides a polynucleotide encoding an antibody or antigen binding fragment or a bispecific antibody. The polynucleotides mentioned are isolatable and include, but are not limited to, DNA, RNA or cDNA, and the like. Isolated polynucleotide sequences encoding bispecific antibodies or antigen-binding fragments can be obtained using methods conventional in the art.
Constructs
To prepare the antibodies of the invention, the polynucleotide sequences encoding the antibodies may be inserted into replicable expression vectors and expressed in host cells or cell-free expression systems. The invention also provides a construct comprising the polynucleotide. A variety of methods commonly used in the art can be used to obtain constructs, including in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombinant techniques, and the like, for example, polynucleotides can be inserted into expression vectors to form constructs at multiple cloning sites. The construct may contain, as desired, various operators such as promoters, terminators, marker genes, etc., which are operably linked to the polynucleotide. Promoters are commonly used to provide signals to initiate transcription, and the promoters may be selected from lactose promoter (Lac), trp promoter, tac promoter, PL and PR promoters of phage, as desired; terminators provide a signal for transcription termination during transcription, and marker genes on constructs are commonly used for screening. Of course, enhancers may also be used as desired to enhance protein expression. The expression vector is not particularly limited, and may be some commercially available expression vectors, or may be an expression vector artificially modified as required, for example, a plasmid, phage, virus, or the like. The virus may be plant cell virus, mammalian cell virus, etc. The construct may express the antibody or protein in vitro, or may be transferred into cells to express the antibody or protein.
Host cells
The invention also provides a host cell containing the polynucleotide or the construct. Any cell suitable for expression of an antibody or protein by a polynucleotide or construct may be used as a host cell. The host cell may be a prokaryotic cell, such as a bacterial cell; eukaryotic cells, such as yeast cells, mammalian cells, and the like, are also contemplated. Typical host cells may be yeast cells, CHO, HEK-293 cells, COS cells, insect cells of Drosophila S2 or Sf 9. Host cells containing the polynucleotide or construct can be obtained by methods commonly used in the art, such as microinjection, electroporation, chemical transfection, virus-mediated transformation, and the like.
Pharmaceutical composition
The invention also provides a pharmaceutical composition comprising: the above antibody or antigen binding fragment, or the above bispecific antibody, and a pharmaceutically acceptable carrier.
The pharmaceutical compositions also include pharmaceutically acceptable salts, such as acid addition salts or base addition salts (e.g., as described in Berge, S.M. et al (1977) J.Pharma.Sci.66:1-19). The pharmaceutically acceptable carrier mentioned is acceptable to the subject at the dosage or concentration employed. Pharmaceutically acceptable carriers include, but are not limited to, buffers or salts such as disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, sodium acetate, citric acid, sodium citrate, tris; sugars, such as trehalose, polysorbate, sucrose, mannitol; surfactants such as polysorbate; preservatives such as chlorhexidine, benzalkonium chloride, benzethonium chloride; amino acids such as histidine, histidine hydrochloride, glycine, glutamine, asparagine, arginine or lysine, etc. Sterile pharmaceutical preparations may be obtained by methods commonly used in the art, for example by filtration through sterile filtration membranes. The pharmaceutical composition can be prepared into various dosage forms, such as freeze-dried dosage forms, injection and the like by selecting different pharmaceutically acceptable carriers according to the requirements of the person skilled in the art. The different pharmaceutical dosage forms prepared may be formulated for administration to a subject by any suitable route of administration including, but not limited to, intravenous, dermal, intramuscular, intraperitoneal, subcutaneous, nasal, oral, rectal, topical, inhalation, transdermal, and the like.
The pharmaceutical compositions mentioned may further comprise other therapeutic agents in addition to the above. The therapeutic agent mentioned is a substance capable of exerting a therapeutic effect. Such as anti-PD-L1 antibodies, anti-CTLA-4 antibodies, anti-TIM-3 antibodies, anti-LAG-3 antibodies, anti-VEGF antibodies, anti-EGFR antibodies, anti-GARP antibodies, anti-CD 3 antibodies, anti-TIGIT antibodies, anti-OX 40 antibodies, anti-TGF-beta antibodies, and the like. By combining these therapeutic antibodies, the therapeutic effect of the disease can be further improved, and thus various diseases can be effectively treated.
Antibody conjugates
The invention also provides an antibody conjugate comprising the bispecific antibody or antigen binding fragment, and a functional small molecule or protease linked to the bispecific antibody or antigen binding fragment. The functional small molecules can be developed or undeveloped small molecule drugs, and the small molecule drugs are chemically coupled with bispecific antibodies or monoclonal antibodies or antigen binding fragments to enhance the treatment effect of the antitumor drugs and reduce adverse reactions. Small molecules such as toxins, chemotherapeutics, photosensitizers, etc. can also be coupled to the mentioned antibodies via linkers. Of course, antibody Protac conjugates can also be obtained by coupling the antibody to a Protac molecule or the like, such as by linking the antibody to a protease targeting ligand (e.g., an E3 ligase ligand) via a linker, bringing the distance between the target protein and the intracellular E3 ubiquitin ligase, and utilizing ubiquitin-proteasome pathway specificity to degrade the target protein.
Kit or medicine box
The invention also provides a kit comprising the bispecific antibody or the monoclonal antibody or the antigen binding fragment. The kit may further include containers, buffer reagents, controls such as positive controls and negative controls, as needed. The person skilled in the art can make the corresponding selections as desired. Accordingly, instructions for use may also be included in the kit to facilitate handling and use by those skilled in the art. In some embodiments, the invention also provides a kit comprising an anti-CD 73 antibody or antigen-binding fragment as described above, or comprising a bispecific antibody as described above. The kit may further comprise an immunotherapeutic agent, wherein the immunotherapeutic agent is one or more of a plurality of therapeutic antibodies, such as an anti-PD-L1 antibody, an anti-PD-1 antibody, or an anti-CTLA-4 antibody. The anti-PD-L1 antibody, anti-PD-1 antibody or CTLA-4 antibody mentioned is a drug which has been marketed or disclosed in the literature or marketed in the future.
Method for producing antibodies
The present invention also provides a method for producing the bispecific antibody, comprising: culturing the host cell and collecting the bispecific antibody from the culture.
The invention also provides a method of producing an antibody or antigen binding fragment comprising: culturing the host cell and collecting the antibody or antigen binding fragment from the culture.
Bispecific antibodies or monoclonal antibodies or antigen-binding fragments collected from the culture may be purified to obtain substantially pure products. By "substantially pure" is meant that the bispecific antibody or monoclonal antibody or antigen binding fragment is more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, and even more than 99.5%, 99.6%, 99.7%, 99.8% pure.
Method for preventing and/or treating diseases
In addition, the present invention also provides a method for preventing and/or treating a disease, comprising: administering to a subject in need thereof an effective amount of the bispecific antibody described above, or the antibody or antigen binding fragment mentioned above.
By "treatment" is meant that can result in a decrease in the severity of symptoms of the disease, an increase in the frequency and duration of the disease asymptomatic phase, or a decrease in pain caused by the disease. The effective amount of antibody used to prevent the disease will generally be less than the effective amount of antibody used to treat the disease. An "effective amount" is an amount sufficient to achieve, or at least partially achieve, the desired effect. After treatment with the bispecific antibody or monoclonal antibody or antigen binding fragment, the inhibition rate of cells in the subject is 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, even 90% or more, or 95% or more, as compared to the subject not treated with the antibody. The subject may be an animal or a human. For example, mammals, including cattle, sheep, mice, horses, etc.
The provided bispecific antibodies or monoclonal antibodies or antigen binding fragments thereof can be used for treating diseases including, but not limited to, cancer, inflammatory diseases, chronic infections, cardiovascular and cerebrovascular diseases, fibrosis, neurodegenerative diseases, immunoregulatory diseases, central nervous system diseases, diabetes, and the like. In some embodiments, the methods provided herein can be used to treat diseases associated with the CD73 target, as well as PD-1/PD-L1. The cancers mentioned include, but are not limited to, non-small cell lung cancer, squamous cell carcinoma, glioma, colon cancer, renal cancer, urothelial cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastrointestinal cancer, esophageal cancer, prostate cancer, cervical cancer, uterine cancer, head and neck cancer, adrenal cancer, urinary tract cancer, vaginal cancer, bladder cancer, melanoma, hematological cancer, and the like. In some embodiments, the disease mentioned is non-small cell lung cancer, melanoma.
The mentioned antibodies or antigen binding fragments or bispecific antibodies can also be used in combination with other therapeutic means for the treatment of diseases. Other treatments mentioned may be chemotherapy or radiotherapy, etc. The treatment effect of the medicine can be further improved and the treatment effect of a patient can be improved by combining treatment means such as chemotherapy or radiotherapy clinically.
The application also provides the use of a bispecific antibody or monoclonal antibody or antigen binding fragment in the preparation of a medicament or kit. The medicament is for the treatment of cancer. The bispecific antibody or monoclonal antibody or antigen binding fragment can be used for preparing medicines for treating various diseases. Can also be used for preparing a kit and used as an immunodiagnosis reagent.
The technical scheme of the present application will be described in detail with reference to examples. It should be noted that these examples are only for facilitating understanding of those skilled in the art and should not be construed as limiting the scope of the present application. The following detailed description of embodiments of the application is exemplary and intended to be illustrative of the application and not to be construed as limiting the application. The PD-L1 binding moiety derived from the second antigen binding moiety is a nanobody obtained by alpaca immunization, the sequence preparation and the manner of obtaining of which are described in PCT international patent application text with application number PCT/CN2022/110423, international publication number WO 2023/01614A, the contents of which are incorporated herein in whole or in part as required. Firstly, an anti-PD-L1 nano library is obtained by an alpaca immunization method, and candidate nano antibodies are obtained by screening and identifying. The method comprises the following steps: mixing fusion protein consisting of human PD-L1 protein extracellular domain sequence and human immunoglobulin Fc region sequence with Freund's adjuvant, emulsifying, immunizing healthy alpaca, and stimulating B cell to express antigen-specific nano antibody. Then, alpaca blood is collected, lymphocytes are separated, total RNA is extracted by adopting a Trizol method, cDNA is obtained by reverse transcription, and VHH antibody gene fragments are obtained by PCR amplification from the reverse transcribed cDNA. In the competent yeast of the common electrotransformation of VHH gene fragment and yeast display carrier, the yeast homologous recombinase connects the fragment and carrier to form complete plasmid, establish library of yeast transformant with high library insertion rate and excellent diversity, and keep stable passage in the auxotroph medium. And incubating yeast cells expressing the antibodies and magnetic beads enriched with target protein antigens, and after multiple enrichment culture, identifying the magnetic bead enriched products by using a flow cytometer and sorting. After multiple rounds of screening, 5 positive clones with high expression are obtained through screening and are respectively named as antibodies A to E. The amino acid sequence of the antibody A is shown as SEQ ID NO. 90, the amino acid sequence of the antibody B is shown as SEQ ID NO. 91, the amino acid sequence of the antibody C is shown as SEQ ID NO. 92, the amino acid sequence of the antibody D is shown as SEQ ID NO. 93, and the amino acid sequence of the antibody E is shown as SEQ ID NO. 94. The humanized antibody is an antibody Ahu, and the amino acid sequence is shown as SEQ ID NO. 95; antibody Bhu, the amino acid sequence of which is shown as SEQ ID NO. 96; the amino acid sequence of the antibody Chu is shown as SEQ ID NO. 97; the amino acid sequence of the antibody D1hu is shown as SEQ ID NO. 98; the amino acid sequence of the antibody D2hu is shown as SEQ ID NO. 99.
The antibodies and humanized antibodies have high binding activity to hPD-L1 and cynomolgus monkey PD-L1 proved by FACS and ELISA experiments. But also shows blocking activity against PD-1/PD-L1 and blocking activity against CD 80/PD-L1.
For example, the binding activity of the antibody to human PD-L1 is detected by FACS. The experimental process is as follows: the affinity of different antibodies to the antigen was detected using a flow cytometer. MDA-MB-231 cells endogenously expressing PD-L1 antigen were cultured at 1X 10 5 The individual/well was added to a 96-well plate. Samples of different concentrations were then added and incubated at 4 degrees celsius for 30 minutes. A fluorescently labeled goat anti-human IgG secondary antibody (manufacturer: abcam) was then added to detect antibodies bound to the cell surface. Generating an antibody-antigen binding dose response curve using geometry values and using Graphpad PrismV6.0 software plots the four parameter raw data to determine EC50 results for antibodies binding to the antigen. Experimental results show that the EC50 values of antibody A, antibody B, antibody C, antibody D and antibody E are 0.089nM, 0.031nM, 0.042nM, 0.039nM, 0.053nM, respectively, and similar to positive controls (Abilib, 0.059 nM), showing high binding activity. The binding activity of the humanized antibodies was determined using a similar method, and the EC50 values of antibody Ahu, antibody Bhu, antibody Chu, antibody D1hu, antibody D2hu were 0.051nM, 0.18nM, 0.023M, 0.18nM and 0.29nM, respectively.
The blocking activity of the antibodies against PD-1/PD-L1 is determined, for example, by FACS. The experimental process is as follows: the blocking effect of the antibodies on PD-1 and its ligand PD-L1 was detected using a competitive flow cell-based method. Resuscitates the PD-1 overexpressing 293T-PD-1 cell line (manufacturer: kang Yuanbo, biotechnology (Beijing) Co., ltd.) cells were grown at 1X 10 5 Each well was plated in a 96-well plate, and antibody dilutions (initial working concentration 200nM, 4-fold dilution) and PD-L1-Biotin dilutions (2 ug/ml,50 ul/well) were mixed and incubated at room temperature for 30 minutes. The mixture was then added to the cells at 100ul per well, mixed well, incubated at 4℃for 60 min, then washed with FACS-containing buffer (PBS with 2% FBS), centrifuged at 1200rpm for 4 min, and the supernatant discarded. PE-labeled streptavidin was added at 100 ul/well and incubated for 30 min in the dark, after which time the incubation was washed with FACS buffer. Cells were resuspended by adding 120ul of FACS buffer and detected on-press. Live cells were shoot according to FSC/SSC and their mean fluorescence values were measured. Antibody-antigen blocking response curves were generated using geometry values and four parameter plots were plotted using Graphpad Prism V6.0 software to determine IC50 values. The experimental results show that the IC50 values of the antibody A, the antibody B, the antibody C, the antibody D and the antibody E are respectively 1.0nM, 2.1nM, 1.7nM, 2.1nM and 2.5nM, and the antibodies can block the binding of the antigen and the ligand thereof. The blocking activity of the humanized antibodies was determined by a similar method, and the IC50 values of antibodies Ahu, bhu, chu, D1hu, and D2hu were 4.0nM, 3.4nM, 1.0nM, 2.6nM, and 12nM, respectively.
The blocking activity of the antibodies against CD-80/PD-L1 was determined by FACS. The experimental process is as follows: using competition-basedFlow cytometry methods to detect the blocking effect of antibodies on PD-L1 and CD-80. Resuscitates 293T-PD-L1 cell line (manufacturer: kang Yuanbo, biotechnology (Beijing) Co., ltd.) over-expressing PD-L1, 1X 10 cells were isolated 5 Each well was plated in 96-well plates, and antibody dilutions (200 nM at initial working concentration, 4-fold dilution) were added to the cells and incubated at 4℃for 60 min. After the incubation, the cells were washed with FACS-containing buffer, centrifuged at 1200rpm for 4 minutes, and the supernatant was discarded. human-CD80-mFc (2 ug/ml) was then added at 100 ul/well and incubated at 4℃for 30 minutes in the absence of light. After incubation, the cells were washed with FACS buffer. 100ul of a 1:200 dilution of a fluorescence-labeled goat anti-mouse secondary antibody (manufacturer: abcam) was added to each well and incubated at 4℃for 30 minutes in the absence of light. After incubation, the cells were washed with FACS buffer and run on a flow machine. Its average fluorescence value was measured. Antibody-antigen blocking response curves were generated using geometry values and four parameter plots were plotted using Graphpad Prism V6.0 software to determine IC50 values. The experimental results show that the IC50 values of the antibody A, the antibody B, the antibody C, the antibody D and the antibody E are respectively 4.0nM, 3.4nM, 4.1nM, 4.8nM and 3.0nM, and the antibodies can block the binding of the antigen and the ligand thereof. Similar methods determine the blocking activity of the humanized antibodies, antibodies Ahu, bhu, chu and D1hu, with IC50 values of about 1.8nM, 1.7nM, 3.2nM and 1.5nM, respectively.
EXAMPLE 1 preparation of monoclonal antibodies
Mice were immunized with CD73 antigen and screened by hybridoma means to obtain monoclonal antibodies. Mouse myeloma cells and mouse spleen cells were fused and the fused cells plated. Then adding HAT selective medium for screening, myeloma cells can not survive, and spleen cells can survive for a short time. Finally, only the myeloma cells fused with lymphocytes survive, i.e. the hybridoma cells are obtained by screening.
Hybridoma cells capable of producing the specific antibody are then selected by limiting dilution of the cloned cells. The hybridoma cells are diluted multiple times and inoculated on a porous cell culture plate, so that each hole of cells is not more than one, and after clones grow to a certain size, antibodies secreted by cells in supernatant of each hole are detected by ELISA, and culture holes which can be combined with specific antigen (CD 73) are positive holes, and dilution is continued until monoclonal cells are obtained.
By the method, a plurality of positive clones are obtained through screening, and 7 clones with high activity are obtained through differential screening, wherein the clones are respectively numbered as clone309, clone307, clone144, clone235, clone451, clone540 and clone449. All 7 clones obtained showed high affinity to human CD73 antigen, as well as high enzymatic activity blocking activity.
The selected clones were sequenced and the selected cloned variable regions were fused to human derived constant region sequences and constructed into PCDNA3.1 mammalian expression vectors in the form of chimeric antibodies. And then carrying out expression purification on the obtained different antibodies by using a mammalian cell system to obtain different antibodies with the purity of at least more than 90%, wherein the expressed antibodies are respectively numbered as mab309, mab307, mab144, mab235, mab451, mab540 and mab449.
Example 2 identification of antibodies binding Activity to CD73
The ELISA plate was coated with human CD73 (hCD 73, manufacturer: ACRO), 100 ng/well, and incubated overnight at 4 ℃. Then, the wells were washed with PBST, 200ul of 2% BSA was added to each well, and the wells were blocked at 37℃for 1 hour. PBST was used for washing and various concentrations of the antibodies to be tested were added at 100 uL/well (initial concentration of each antibody was 31.25nm, 4-fold gradient dilution) and incubated at 37 ℃ for 2h. PBST was used for washing, and goat anti-human secondary antibody (1% BSA dilution, 1:10000, manufacturer: jackson) was added at 100 uL/well and incubated at 37℃for 1h. After washing with PBST, 100ul of TMB color development solution was added for 10-15min, 50ul of 2M sulfuric acid was added to terminate the reaction. The OD450 values were read using a microplate reader and the EC50 values of the antibodies to be tested were calculated using data processing software Graphpad prism8.0, as shown in table 1 below, wherein the positive control was the anti-CD 73 antibody olecumab (MEDI 9447) from mediune, as Li Kangzi, and the same positive control was used in the following examples.
TABLE 1
The experimental results show that the antibodies can specifically bind to CD 73.
Example 2 antibody binding Activity to MDA-MB-231 cells
The binding activity of the antibody to MDA-MB-231 cells was detected by FACS, with high expression of CD73 antigen on the surface of MDA-MB-231 cells. MDA-MB-231 cells were cultured, and the cell concentration was adjusted to 1-2X 10 6 Each ml was then added to a 96-well plate at 100 ul/well. Centrifugation at 1000rpm for 5min, removal of the culture supernatant, followed by addition of different antibodies to be tested (initial antibody concentration 200nM, 4-fold gradient dilution) at 100 ul/well and incubation at 4℃for 30min. Washing with buffer solution, adding fluorescence labeled goat anti-human secondary antibody (manufacturer: abcam), and incubating at 4deg.C for 30min. The cells were washed 2 times with buffer, resuspended with buffer and the fluorescent signal was detected on-stream. EC50 values of the samples to be tested were calculated using the data processing software Graphpad prism8.0, as shown in table 2 below.
TABLE 2
As can be seen from the results in table 2, all antibodies bind to human CD73 and exhibit properties similar to those of the positive control.
Example 3 Cross-reacting antibodies with monkey CD73
The ELISA plate was coated with monkey CD73 (CynocD 73, manufacturer: ACRO), 100 ng/well, and incubated overnight at 4 ℃. Then, the wells were washed with PBST, 200ul of 2% BSA was added to each well, and the wells were blocked at 37℃for 1 hour. PBST was used for washing, and antibodies to be tested were added at different concentrations (initial concentration of antibody 31.25nM, 4-fold gradient dilution) per well and incubated at 37℃for 2h. PBST was used for washing, and goat anti-human secondary antibody (diluted with 1% BSA, manufacturer: jackson) was added at 100 uL/well and incubated at 37℃for 1h. After washing with PBST, 100ul of TMB color development solution was added for 10-15min, 50ul of 2M sulfuric acid was added to terminate the reaction. The OD450 values were read using a microplate reader and EC50 values of the antibodies to be tested were calculated using data processing software Graphpad prism8.0 as shown in table 3 below.
TABLE 3 Table 3
Antibody numbering | EC50(nM) |
mab309 | 0.028 |
mab307 | 0.013 |
mab144 | 0.027 |
mab235 | 0.020 |
mab451 | 0.024 |
mab540 | 0.041 |
mab449 | 0.030 |
hIgG1 | Not combined with |
Positive control | 0.023 |
The experimental results show that both the listed antibodies show binding activity to cynoCD 73.
Example 4 antibody enzyme Activity blocking assay
MDA-MB-231 tumor cells were cultured under the conditions of DMEM+10% FBS+1% PS. Cells were digested and resuspended and the cell density was adjusted to 4.5X10 5 Each of the cells was plated at 100 ul/well in 96-well cell culture plates. The antibody to be tested was diluted with medium (initial concentration 200nM, 4-fold gradient dilution). Diluting, mixing, adding into cell culture plate at 50 uL/well, and adding 5% CO at 37deg.C 2 After incubation in the incubator for 1h, 50uL of 0.8mM AMP (manufacturer: sigma) was added to each well. Mixing, and placing at 37deg.C and 5% CO 2 Incubate for 2h. Centrifugation is carried out at 1000rpm for 5min, and 50uL of supernatant is pipetted into a new 96-well plate. 50uL 130uM of ATP (manufacturer: sigma) was added to each well. After mixing, 100ul of Cell titer glo detection reagent (manufacturer: promega) was added to each well and incubated for 5-10 minutes in the dark. Fluorescent signals in 96-well plates were read using an enzyme-labeled instrument. Four parameter curves were drawn with the relative fluorescence values as the y-axis and the concentration of the antibody samples as the x-axis. The curve was analyzed using GraphPad Prism 8.0 software and IC50 values of the antibodies were derived.
TABLE 4 Table 4
Antibody numbering | IC50(nM) |
mab144 | 0.30 |
mab235 | 0.22 |
mab451 | 0.25 |
mab540 | 0.18 |
mab449 | 0.15 |
hIgG1 | Unblocked |
Experimental results show that the mab144 antibody, the mab235 antibody, the mab451 antibody, the mab540 antibody and the mab449 antibody all show enzyme activity blocking activity and are similar to the positive control.
EXAMPLE 5 antibody endocytosis assay
MDA-MB-231 tumor cells were cultured, the cells were digested with 0.25% pancreatin and resuspended for counting, and the cell density was adjusted to 1X 10 6 Each of the cells was plated at 100 ul/well in 96-well plates. Centrifugation was carried out at 1000rpm for 5 minutes, and the supernatant was discarded. The antibody to be tested was diluted to 20nM with FACS buffer, then added to a 96-well plate at 100 uL/well, mixed with the cells and placed in a refrigerator at 4℃for 30 minutes. Then centrifuged at 1000rpm for 10min and washed with FACS buffer. One of the samples is marked as 0h, placed on ice and temporarily stored in a refrigerator at 4 ℃, and the other samples are placed in a constant temperature incubator at 37 ℃ for 4h. Then taking out the sample on ice for 0h and the sample at 37 ℃ for 4h, centrifuging to remove the supernatant, adding 100ul of goat anti-human fluorescent secondary antibody (diluted 1:200, abcam), uniformly mixing, and incubating for 30min at 4 ℃. Then washed with FACS buffer. The cells were resuspended with buffer and the fluorescent signal was detected on-stream. Calculating the endocytosis ratio of the antibody according to the read fluorescence signal, wherein the calculation formula is as follows:
Endocytic ratio (%) = (0 h fluorescent signal-4 h fluorescent signal)/0 h fluorescent signal 100%.
The experimental results are shown in FIG. 6. The results indicate that anti-CD 73 antibodies are able to promote endocytosis of CD 73.
EXAMPLE 6 anti-tumor efficacy of antibodies
CT26-hPDL1-hCD73 cells were cultured to the logarithmic growth phase, the cells were collected, the culture solution was removed and washed with PBS, and the cells were inoculated into BALB/C-hPD1/hPDL1/hCD73 triple transgenic mice (humanized mouse model expressing human PD1, human PDL1 extracellular region protein and human CD73 protein, manufacturer: jiangsu Jiech Kangsu Biotech Co., ltd.) at an inoculum size of 1X 10 6 cells/100. Mu.L/cell. When the average tumor volume reaches 80-120mm 3 When left and right, mice were randomly divided into 10 groups of 6 mice each. The day of the grouping was defined as day D0, and the anti-PD-L1 antibody (antibody number D2hu, administration concentration of 1.5mpk (mg/kg)) and the anti-CD 73 antibody (administration concentration of 10 mpk) were administered in combination at day D0 twice a week for two weeks, and by intraperitoneal injection, the tumor volume variation coefficient CV did not exceed 1/3. Tumor volume and mouse body weight were measured 2-3 times per week following dosing, depending on tumor growth. The tumor volume calculation mode is as follows: tumor volume (mm) 3 ) =0.5×tumor long diameter×tumor short diameter 2 . The experimental results are shown in FIG. 7. Wherein G1 is PBS, G2 is anti-PD-L1 antibody (administration concentration is 1.5 mpk), G3 is anti-PD-L1 antibody and mab307 antibody are administered in combination, G4 is anti-PD-L1 antibody and mab309 antibody are administered in combination, G5 is anti-PD-L1 antibody and mab235 antibody are administered in combination, G6 is anti-PD-L1 antibody and mab540 antibody are administered in combination, G7 is anti-PD-L1 antibody and mab144 antibody are administered in combination, G8 is anti-PD-L1 antibody and mab449 antibody are administered in combination, and G9 is anti-PD-L1 antibody and mab451 antibody are administered in combination.
The results showed that the mouse antitumor efficacy of the mab309 antibody, the mab307 antibody, the mab235 antibody, the mab540 antibody, the mab144 antibody, the mab449 antibody, the mab451 antibody in combination with the PD-L1 antibody was superior to that of the PD-L1 antibody alone.
Example 7
The humanized antibody is obtained by a complementarity determining region Grafting method (CDR-Grafting method), and the humanized antibody is obtained by uniformly dividing the amino acid sequences of the antibody and the template into an FR region and a CDR region, and then Grafting the CDR region onto the FR region of the template, so that the CDR region determining the specificity of the antibody and the framework region of the humanized antibody are mutually combined. Meanwhile, in order to avoid the decrease of the affinity of the antibody, key amino acid residue sites are calculated by computer simulation and other technologies, and the affinity of the humanized antibody is ensured by a back mutation method. Humanized antibodies of the above antibodies were obtained, and the humanized antibodies were named after the numbering of the antibodies by adding the letter "hu" with different numbers to represent different humanized antibodies. In addition, the Fc region of the antibody human source is mutated, and the letter "mu" is added as a suffix to the mutated antibody when it is named. One of the mutations includes the L234F, L235E, P S and N297A mutations, and the mutated antibodies are given the letter "mu1" as suffix in the naming. Another mutation includes the K214R, L234F, L E, P35331S, D E and L358M mutations, and the mutated antibody is added with the letter "mu2" as a suffix when named. For example, mab309hu1 represents a first antibody where the mab309 antibody was humanized. mab144hu2 represents a second antibody to which the mab144 antibody was humanized. mab309hu3mu represents a third antibody where the mab309 antibody was humanized while the Fc region of the antibody was mutated.
Example 8 humanized antibodies binding Activity to MDA-MB-231 cells
MDA-MB-231 cells with high expression of CD73 antigen on their surface are added into 96-well plate at 100 ul/well to obtain cell concentration of 1-2×10 6 And each ml. Washed with FACS buffer (i.e., PBS containing 2% FBS), then added with different antibodies to be tested (initial antibody concentration 200nM, 4-fold gradient dilution) at 100 ul/well and incubated at 4℃for 30min. Washing with buffer solution, adding fluorescence labeled goat anti-human secondary antibody (manufacturer: abcam), and incubating at 4deg.C for 30min. The cells were washed 2 times with buffer, resuspended with buffer and the fluorescent signal was detected on-stream. EC50 values of the samples to be tested were calculated using the data processing software Graphpad prism8.0, as shown in table 5 below.
TABLE 5
Antibody numbering | EC50(nM) |
mab309hu1mu1 | 1.1 |
mab309hu3mu1 | 3.0 |
mab144hu2mu1 | 1.5 |
mab451hu4mu1 | 0.68 |
mab451hu5mu1 | 0.88 |
mab451hu6mu1 | 0.73 |
mab540hu1mu1 | 1.3 |
mab540hu3mu1 | 0.87 |
mab449hu4mu1 | 0.53 |
Positive control | 0.55 |
hIgG1 | Not combined with |
The humanized antibodies showed high binding activity to MDA-MB-231 cells, similar to the positive control.
Example 9 Activity of blocking the Activity of humanized antibody
Culturing A375 tumor cells, digesting the cells with 0.25% pancreatin to adjust the cell density to 4.5X10 5 Each of the cells was plated at 100 ul/well in 96-well cell culture plates. Different antibodies to be tested were diluted with medium (initial concentration 200nM, 4-fold gradient dilution). Diluting, mixing, adding into cell culture plate at 50 uL/well, and adding 5% CO at 37deg.C 2 After incubation in the incubator for 1h, 50uL of 0.8mM AMP (manufacturer: sigma) was added to each well. Mixing at 37deg.C with 5% CO 2 Incubate for 2h. Centrifugation at 1000rpm for 5min, 50uL of supernatant was pipetted onto a fresh 96-well cell culture plate, and 50uL 130uM of ATP (manufacturer: sigma) was added per well. After mixing, 100ul of Cell titer glo detection reagent (manufacturer: promega) was added to each well. Incubate for 5-10 min in the dark and read fluorescence signals in 96-well plates with an enzyme-labeled instrument. Four parameter curves were drawn with the relative fluorescence values as the y-axis and the concentration of the antibody samples as the x-axis. The curves were analyzed using GraphPad Prism 8.0 software and IC50 values for the antibodies were obtained as shown in table 6 below.
TABLE 6
Antibody numbering | IC50(nM) |
mab144hu1mu1 | 0.087 |
mab144hu2mu1 | 0.055 |
mab449hu4mu1 | 0.061 |
mab451hu4mu1 | 0.072 |
mab451hu5mu1 | 0.049 |
mab451hu6mu1 | 0.035 |
hIgG1 | Unblocked |
The results indicate that the humanized antibody exhibits enzyme activity blocking activity.
EXAMPLE 10 construction of bispecific antibodies
Genetic engineering of an anti-CD 73 antibody as a first antigen-binding portion and an anti-PD-L1 fragment as a second antigen-binding portion to construct a bispecific antibody wherein the anti-PD-L1 fragment is passed through (G 4 S) 4 The joints are connected together. During ligation, the anti-PD-L1 fragment is ligated to the carboxy terminus of the heavy chain constant region domain CH3 of the IgG type structure. There is a carboxyl-terminal linkage of the heavy chain constant region domain CH3 of the anti-PD-L1 single domain antibody (anti-PD-L1 single domain antibody, numbered D2 hu) and the IgG structure, respectively, as shown in FIG. 1. The bispecific antibodies formed are numbered beginning with "b". For example, b144mu-D12hu represents a bispecific antibody formed by a mab144 antibody (with a mutation in the Fc region) as the first antigen-binding moiety and D2hu as the second antigen-binding moiety. For another example, b144hu2mu1-D2hu represents a bispecific antibody formed by humanizing mab144 with a second antibody (with a first mutation in the Fc region) as the first antigen-binding moiety and D2hu as the second antigen-binding moiety. And so on.
Then, the bispecific antibody protein is produced by transiently transfecting CHO-S cells, the supernatant is collected and purified by a protein A affinity column, the purity of the purified antibody is measured by HPLC and SDS-PAGE, and the purity of the bispecific antibody is determined to be more than 90% by detection.
EXAMPLE 11 bispecific antibody binding Activity
CHO-K1-CD73 overexpressing cells were added to 96-well plates at a cell concentration of 1-2X 10 at 100 ul/well 6 And each ml. Washed with FACS buffer (i.e., PBS containing 2% FBS), then added with different antibodies to be tested (initial antibody concentration 200nM, 4-fold gradient dilution) at 100 ul/well and incubated at 4℃for 30min. Washing with buffer solution, adding fluorescence labeled goat anti-human secondary antibody (manufacturer: abcam), and incubating at 4deg.C for 30min. Washing with buffer solution, adding buffer solution to re-suspend the cells, and detecting fluorescent signals by a flow type machine. EC50 values of the samples to be tested were calculated using the data processing software Graphpad prism8.0, as shown in table 7 below.
TABLE 7
Antibody numbering | EC50(nM) |
b144mu1-D2hu | 1.5 |
b144hu2mu1-D2hu | 1.8 |
b449mu1-D2hu | 0.28 |
b309mu1-D2hu | 0.50 |
b451mu1-D2hu | 0.67 |
hIgG | Not combined with |
Example 12 determination of bispecific antibody Activity blocking Activity
The enzyme activity blocking activity of the bispecific antibody was examined by the method of reference example 9, and the results are shown in tables 8-1 and 8-2 and FIG. 8. The enzyme activity blocking activity of the bispecific antibody is stronger than that of the positive control, and is at least 2-5 times that of the positive control.
TABLE 8-1
TABLE 8-2
Antibody numbering | EC50(nM) |
b144hu2mu2-D2hu | 0.40 |
mab144hu2mu2 | 0.30 |
mab449hu4mu1 | 0.42 |
b451hu4mu1-D2hu | 0.68 |
mab451hu4mu2 | 0.25 |
hIgG | Unblocked |
hIgG1mu2 | Unblocked |
Example 13 bispecific antibody reporter blocking Activity
The blocking effect of bispecific antibodies on the PD-L1/PD-1 pathway was investigated by reporter experiments. The experiment was performed with the aid of two cell lines, jurkat-PD1-CD3zeta-NFAT-Luc2 cell line (manufacturer: kang Yuanbo, biotechnology (Beijing) Co.) and 293T-hPD-L1 cell line (manufacturer: kang Yuanbo, biotechnology (Beijing) Co.). The Jurkat-PD1-CD3zeta-NFAT-Luc2 cell strain stably expresses fusion protein composed of PD-1ECD and CD3zeta in Jurkat cells, and simultaneously inserts a luciferase reporter gene driven by NF-AT; 293T-hPD-L1 cells are 293T cells expressing human PD-L1. When two cells are co-cultured, the PD-1/PD-L1 interaction is used as a first signal, the intracellular CD3zeta chain is used as a second signal to transmit an activation signal inwards, and the NFAT driven luciferase reporter gene is expressed and emits fluorescence; when the PD-L1 antibody is added into a culture system, the combination of the PD-1/PD-L1 is blocked, the transmission of an activation signal is inhibited, and the luciferase reporter gene cannot be expressed. The experimental procedure was as follows:
293T-hPD-L1 cells were cultured at a rate of 2X 10 4 The wells/well were plated in 96-well plates and Jurkat-PD1-CD3zeta-NFAT-Luc2 effector cells were plated in 2X 10 4 Well continue to be added to 96-well plates; then adding the antibodies to be detected with different concentrations (initial concentration is 60ug/ml, 4-time gradient dilution) at 37 DEG CIncubate for 18-24h. 100ul of luciferase substrate ONE-Glo was added per well TM Luciferase Assay system detection reagent, incubating for 5 minutes in the absence of light; the microplate reader reads the fluorescent signal in the 96-well plate. Four parameter curves were drawn with the relative fluorescence values as the y-axis and the concentration of the antibody samples as the x-axis. The curve was analyzed using GraphPad Prism 8.0 software and the IC50 values of the diabodies were obtained as shown in tables 9-1 and 9-2 below.
TABLE 9-1
TABLE 9-2
Antibody numbering | IC50(nM) |
b144hu2mu2-D2hu | 4.6 |
b451hu4mu2-D2hu | 5.1 |
D2hu | 5.0 |
hIgG1mu2 | Unblocked |
In the description of the present specification, a description of the terms "embodiment," "some embodiments," "examples," "detailed description," or "implementation," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (19)
1. An anti-CD 73 antibody or antigen-binding fragment comprising a heavy chain variable region and a light chain variable region, said heavy chain variable region:
comprises the HCDR sequences shown in SEQ ID NO. 1, 2 and 3, or a sequence having one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 1, 2 and 3;
or comprises the HCDR sequences shown in SEQ ID NOs 4, 5 and 6, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOs 4, 5 and 6;
or comprises the HCDR sequences shown in SEQ ID NO. 7, 8 and 9, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 7, 8 and 9;
or comprises the HCDR sequences shown in SEQ ID NOS 10, 11 and 12, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS 10, 11 and 12;
Or comprises the HCDR sequences shown in SEQ ID NO 13, 14 and 15, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO 13, 14 and 15;
or comprises the HCDR sequences shown in SEQ ID NOS.16, 17 and 18, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NOS.16, 17 and 18;
or comprises the HCDR sequences shown in SEQ ID NO. 19, 20 and 21, or has one, two or three conservative amino acid mutations with the HCDR sequences shown in SEQ ID NO. 19, 20 and 21;
the light chain variable region:
comprises the LCDR sequences shown in SEQ ID NOs 22, 23 and 24, or a sequence having one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOs 22, 23 and 24;
or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 25, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 25;
or comprises the LCDR sequences shown in SEQ ID NOS.26, 27 and 28, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.26, 27 and 28;
Or comprises the LCDR sequences shown in SEQ ID NOS.29, 30 and 31, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.29, 30 and 31;
or comprises the LCDR sequences shown in SEQ ID NOS.22, 23 and 32, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.22, 23 and 32;
or comprises the LCDR sequences shown in SEQ ID NOS.33, 34 and 35, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.33, 34 and 35;
or comprises the LCDR sequences shown in SEQ ID NOS.36, 37 and 38, or has one, two or three conservative amino acid mutations with the LCDR sequences shown in SEQ ID NOS.36, 37 and 38.
2. The antibody or antigen-binding fragment of claim 1, which is selected from at least one of the following:
(1) Comprises the HCDR sequences shown in SEQ ID NO 1, 2 and 3, and the LCDR sequences shown in SEQ ID NO 22, 23 and 24; or alternatively
(2) Comprises the HCDR sequences shown in SEQ ID NO. 4, 5 and 6, and the LCDR sequences shown in SEQ ID NO. 22, 23 and 25; or alternatively
(3) Comprises the HCDR sequences shown in SEQ ID NO 7, 8 and 9, and the LCDR sequences shown in SEQ ID NO 26, 27 and 28; or alternatively
(4) Comprises the HCDR sequences shown in SEQ ID NO 10, 11 and 12, and the LCDR sequences shown in SEQ ID NO 29, 30 and 31; or alternatively
(5) Comprises the HCDR sequences shown in SEQ ID NO 13, 14 and 15, and the LCDR sequences shown in SEQ ID NO 22, 23 and 32; or alternatively
(6) Comprises the HCDR sequences shown in SEQ ID NOS.16, 17 and 18, and the LCDR sequences shown in SEQ ID NOS.33, 34 and 35; or alternatively
(7) Comprises the HCDR sequences shown in SEQ ID NO 19, 20 and 21, and the LCDR sequences shown in SEQ ID NO 36, 37 and 38.
3. An anti-CD 73 antibody or antigen-binding fragment comprising a heavy chain variable region comprising complementarity determining regions HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein
HCDR1 is selected from the sequences shown in SEQ ID NO 1 or 4 or 7 or 10 or 13 or 16 or 19,
HCDR2 is selected from the sequences shown in SEQ ID NO 2 or 5 or 8 or 11 or 14 or 17 or 20,
HCDR3 is selected from the sequences shown in SEQ ID NO 3 or 6 or 9 or 12 or 15 or 18 or 21,
LCDR1 is selected from the sequences shown in SEQ ID NO. 22 or 26 or 29 or 33 or 36,
LCDR2 is selected from the sequences shown in SEQ ID NO 23 or 27 or 30 or 34 or 37,
LCDR3 is selected from the sequences shown in SEQ ID NO 24 or 25 or 28 or 31 or 32 or 35 or 38.
4. An anti-CD 73 antibody or antigen-binding fragment comprising:
the HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region as shown in SEQ ID NO 39 or 40 or 41 or 42 or 43 or 44 or 45 and the LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region as shown in SEQ ID NO 46 or 47 or 48 or 49 or 50 or 51 or 52.
5. The antibody or antigen-binding fragment of any one of claims 1-4, comprising:
a heavy chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence shown in SEQ ID NO 39 or 40 or 41 or 43 or 44 or 45 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65, and
a light chain variable region having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO 46 or 47 or 48 or 50 or 52 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79.
6. The antibody or antigen-binding fragment of any one of claims 1 to 5, which is selected from at least one of the following:
has a heavy chain variable region shown in SEQ ID NO. 39 and a light chain variable region shown in SEQ ID NO. 46; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 40 and a light chain variable region shown in SEQ ID NO. 47; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 41 and a light chain variable region shown in SEQ ID NO. 48; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 42 and a light chain variable region shown in SEQ ID NO. 49; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 43 and a light chain variable region shown in SEQ ID NO. 50; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 44 and a light chain variable region shown in SEQ ID NO. 51; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 45 and a light chain variable region shown in SEQ ID NO. 52; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 53 and a light chain variable region shown in SEQ ID NO. 66; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 54 and a light chain variable region shown in SEQ ID NO. 67; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 55 and a light chain variable region shown in SEQ ID NO. 68; or alternatively
Has a heavy chain variable region shown as SEQ ID NO. 56 and a light chain variable region shown as SEQ ID NO. 69; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 57 and a light chain variable region shown in SEQ ID NO. 70; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 58 and a light chain variable region shown in SEQ ID NO. 71; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 59 and a light chain variable region shown in SEQ ID NO. 72; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 60 and a light chain variable region shown in SEQ ID NO. 73; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 60 and a light chain variable region shown in SEQ ID NO. 74; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 61 and a light chain variable region shown in SEQ ID NO. 75; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 62 and a light chain variable region shown in SEQ ID NO. 76; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 63 and a light chain variable region shown in SEQ ID NO. 77; or alternatively
Has a heavy chain variable region shown as SEQ ID NO. 64 and a light chain variable region shown as SEQ ID NO. 78; or alternatively
Has a heavy chain variable region shown in SEQ ID NO. 65 and a light chain variable region shown in SEQ ID NO. 79.
7. The antibody or antigen-binding fragment of any one of claims 1 to 6, wherein the antibody is selected from at least one of the group consisting of: igG1, igG2, igG3, igG4, or variants thereof;
Optionally, the antibody or antigen binding fragment has at least one of the following properties:
(a) Inhibition of CD73 enzymatic activity;
(b) Binding to human CD73 with a Kd of 10nM or less;
(c) Monkey CD73 was bound with a Kd of 10nM or less.
8. A bispecific antibody comprising a first antigen-binding portion and a second antigen-binding portion;
the first antigen binding portion specifically binds to a first epitope, the first antigen binding portion comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region and the light chain variable region being the heavy chain variable region and the light chain variable region of the antibody or antigen binding fragment of any one of claims 1-7;
the second antigen binding portion specifically binds to a second epitope, the second antigen binding portion being fused to the first antigen binding portion;
optionally, the second antigen binding portion specifically binds to at least one of: PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, 4-1BB, OX40, VEGF trap, VEGFR, EGFR, GARP, TGF-beta, CD47, c-Met, CD3, CD33, TIGIT, PVRIG, CD96, LEFA1, CD226, FAP2, GITR, VISITA, claudin 18.2, ICOS, BTLA, B7-H3, BCMA, MUC1/16;
Optionally, the first antigen binding portion is selected from at least one of:
(1) Has the HCDR sequences shown in SEQ ID NO 1, 2 and 3, and the LCDR sequences shown in SEQ ID NO 22, 23 and 24; or alternatively
(2) Has the HCDR sequences shown in SEQ ID NO. 4, 5 and 6, and the LCDR sequences shown in SEQ ID NO. 22, 23 and 25; or alternatively
(3) Has the HCDR sequences shown in SEQ ID NO 7, 8 and 9, and the LCDR sequences shown in SEQ ID NO 26, 27 and 28; or alternatively
(4) Has the HCDR sequences shown in SEQ ID NO 10, 11 and 12, and the LCDR sequences shown in SEQ ID NO 29, 30 and 31; or alternatively
(5) Has the HCDR sequences shown in SEQ ID NO 13, 14 and 15, and the LCDR sequences shown in SEQ ID NO 22, 23 and 32; or alternatively
(6) Has the HCDR sequences shown in SEQ ID NO 16, 17 and 18, and the LCDR sequences shown in SEQ ID NO 33, 34 and 35; or alternatively
(7) Has the HCDR sequences shown in SEQ ID NO 19, 20 and 21, and the LCDR sequences shown in SEQ ID NO 36, 37 and 38.
9. The bispecific antibody of claim 8, wherein the heavy chain variable region and heavy chain constant domain of the first antigen binding portion are linked, and the light chain variable region and light chain constant domain of the first antigen binding portion are linked to form an IgG-like structure;
The second antigen binding portion is linked to the IgG-like structure, the second antigen binding portion comprising a single domain antibody that specifically binds to a second epitope;
optionally, the second antigen binding portion comprises a single domain antibody that specifically binds a second epitope selected from at least one of PD-1, PD-L1, VEGF trap, TGF- β, GARP, TIGIT, PVRIG, CD 96;
optionally, the second antigen binding portion comprises CDR1, CDR2, and CDR3, the second antigen binding portion being selected from at least one of:
(1) Has a CDR1 sequence shown as SEQ ID NO. 80, a CDR2 sequence shown as SEQ ID NO. 81 and a CDR3 sequence shown as SEQ ID NO. 82; or alternatively
(2) Has a CDR1 sequence shown as SEQ ID NO. 83, a CDR2 sequence shown as SEQ ID NO. 84 and a CDR3 sequence shown as SEQ ID NO. 85; or alternatively
(3) Has a CDR1 sequence shown as SEQ ID NO. 86, a CDR2 sequence shown as SEQ ID NO. 87 and a CDR3 sequence shown as SEQ ID NO. 88; or alternatively
(4) Has a CDR1 sequence shown in SEQ ID NO. 80, a CDR2 sequence shown in SEQ ID NO. 81 and a CDR3 sequence shown in SEQ ID NO. 89;
optionally, the second antigen binding portion is selected from the group consisting of:
(a) Has a sequence as shown in SEQ ID NO 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99;
(b) Sequences having 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity than (a).
10. The bispecific antibody of claim 8, wherein the heavy chain variable region and heavy chain constant domain of the first antigen binding portion are linked, and the light chain variable region and light chain constant domain of the first antigen binding portion are linked, forming an IgG type structure;
the second antigen binding portion is linked to the carboxy terminus (C-terminus) of the Fc region; or alternatively
The second antigen binding portion is linked to the amino terminus (N-terminus) of the heavy chain variable region or the light chain variable region of the first antigen binding portion; or alternatively
The second antigen binding portion is linked to the carboxy terminus (C-terminus) of the light chain constant domain CL;
optionally, the bispecific antibody has at least one of the following properties:
(a) Specifically binds to PD-L1 with an EC50 value of 10nM or less;
(b) Specifically binds to CD73 with an EC50 value of 10nM or less;
(c) Has antitumor activity;
(d) Promoting CD73 endocytosis.
11. A polynucleotide encoding the antibody or antigen-binding fragment of any one of claims 1 to 7 or encoding the bispecific antibody of any one of claims 8 to 10.
12. A construct comprising the polynucleotide of claim 11.
13. A host cell comprising the polynucleotide of claim 11 or the construct of claim 12.
14. A pharmaceutical composition comprising:
the antibody or antigen-binding fragment of any one of claims 1 to 7, or the bispecific antibody of any one of claims 8 to 10; and
a pharmaceutically acceptable carrier.
15. An antibody conjugate, comprising:
the antibody or antigen-binding fragment of any one of claims 1 to 7, or the bispecific antibody of any one of claims 8 to 10; and
a functional small molecule linked to the antibody or antigen-binding fragment or the bispecific antibody.
16. A kit comprising the antibody or antigen-binding fragment of any one of claims 1 to 7 or the bispecific antibody of any one of claims 8 to 10.
17. A method of producing the antibody or antigen-binding fragment of any one of claims 1 to 7 or producing the bispecific antibody of any one of claims 8 to 10, comprising:
culturing the host cell of claim 13, and
collecting said antibody or antigen binding fragment or said bispecific antibody from the culture.
18. A method for preventing and/or treating a disease, comprising:
administering to a subject in need thereof an effective amount of the antibody or antigen-binding fragment of any one of claims 1-7, or the bispecific antibody of any one of claims 8-10, or the pharmaceutical composition of claim 14, or the antibody conjugate of claim 15;
optionally, the disease is selected from cancer or autoimmune disease.
19. Use of the antibody or antigen-binding fragment of any one of claims 1 to 7, or the bispecific antibody of any one of claims 8 to 10, in the manufacture of a medicament or kit or antibody conjugate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310968592.5A CN116813786A (en) | 2023-08-03 | 2023-08-03 | anti-CD 73 antibody and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310968592.5A CN116813786A (en) | 2023-08-03 | 2023-08-03 | anti-CD 73 antibody and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116813786A true CN116813786A (en) | 2023-09-29 |
Family
ID=88143139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310968592.5A Pending CN116813786A (en) | 2023-08-03 | 2023-08-03 | anti-CD 73 antibody and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116813786A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107001474A (en) * | 2014-11-21 | 2017-08-01 | 百时美施贵宝公司 | Anti- CD73 antibody and application thereof |
CN109154611A (en) * | 2015-12-09 | 2019-01-04 | 科尔沃斯制药股份有限公司 | The anti-CD73 antibody of humanization |
CN112513089A (en) * | 2018-11-12 | 2021-03-16 | 江苏恒瑞医药股份有限公司 | anti-CD 73 antibody, antigen binding fragment thereof and application |
WO2022179039A1 (en) * | 2021-02-24 | 2022-09-01 | 苏州近岸蛋白质科技股份有限公司 | Anti-human cd73 antibody and use thereof |
-
2023
- 2023-08-03 CN CN202310968592.5A patent/CN116813786A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107001474A (en) * | 2014-11-21 | 2017-08-01 | 百时美施贵宝公司 | Anti- CD73 antibody and application thereof |
CN113773388A (en) * | 2014-11-21 | 2021-12-10 | 百时美施贵宝公司 | anti-CD 73 antibodies and uses thereof |
CN109154611A (en) * | 2015-12-09 | 2019-01-04 | 科尔沃斯制药股份有限公司 | The anti-CD73 antibody of humanization |
CN112513089A (en) * | 2018-11-12 | 2021-03-16 | 江苏恒瑞医药股份有限公司 | anti-CD 73 antibody, antigen binding fragment thereof and application |
WO2022179039A1 (en) * | 2021-02-24 | 2022-09-01 | 苏州近岸蛋白质科技股份有限公司 | Anti-human cd73 antibody and use thereof |
Non-Patent Citations (1)
Title |
---|
LUCA ANTONIOLI, ET: "Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities", TRENDS CANCER, vol. 2, no. 2, 1 February 2016 (2016-02-01), pages 95 - 109, XP055529454, DOI: 10.1016/j.trecan.2016.01.003 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11274142B2 (en) | Fusion protein containing TGF-β receptor and medicinal uses thereof | |
CN113166246A (en) | Antibody and application thereof | |
TWI805121B (en) | AN ANTI-SIRPα ANTIBODY AND AN APPLICATION THEREOF | |
EP3892639A1 (en) | Cd3 antibody and pharmaceutical use thereof | |
KR20230166075A (en) | Multispecific antibodies with specificity for ROR1 and CD3 | |
CN114206931A (en) | anti-PD-1 antibodies and uses thereof | |
CN114502591A (en) | Antibodies targeting BCMA, bispecific antibodies and uses thereof | |
CN116829587A (en) | HER2 antibodies and uses thereof | |
TWI806088B (en) | Binding protein with structure of H2L2 and HCAb | |
CN114667296B (en) | Bispecific antibody and application thereof | |
CN116209680A (en) | Novel human antibodies that bind to human CD3 epsilon | |
TW202128747A (en) | Tgf-beta-rii binding proteins | |
CN116813786A (en) | anti-CD 73 antibody and application thereof | |
WO2024078558A1 (en) | Anti-cd100 antibody and use thereof | |
CN114573704B (en) | PD-1/CTLA-4 binding protein and medical application thereof | |
WO2023040945A1 (en) | Protein specifically binding to pd-1 and pharmaceutical use thereof | |
WO2023040940A1 (en) | Use of pvrig/tigit binding protein in combination with immune checkpoint inhibitor in treatment of cancers | |
WO2024017326A1 (en) | Anti-gprc5d nanobody and use thereof | |
WO2023186100A1 (en) | Anti-ror1 antibody and use thereof | |
WO2023051656A1 (en) | Bispecific antibody and application thereof | |
US20230265202A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
WO2023025194A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
US20240124563A1 (en) | Anti-Human MSLN Antibody And Application Thereof | |
KR20240055080A (en) | Proteins that specifically bind to PD-1 and their pharmaceutical uses | |
KR20240049318A (en) | FAP/CD40 binding molecules and their medical uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |